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 ABSTRACT 
Alginate Strings and Their Applications in Spinal Cord Regeneration 
Saravanan Kanakasabai 
Margaret A. Wheatley, Ph.D. 
 
 
Spinal cord injury leads to severing of neurons of the central nervous system (CNS) that 
are responsible for communication between the brain and other parts of the body. The 
presence of inhibiting factors following injury limits neuronal regeneration leading to 
paraplegia or quadriplegia depending on the level of the injury. The goal of this study 
was to design and develop a graft that would aid in neuronal adhesion as well as enhance 
neuronal regeneration and also act as a physical bridge at the site of injury. Alginate a 
polysaccharide derived from brown sea weed was employed in making the graft because 
of its ability to form gels in the presence of a polycation solution and also allows 
modification with growth permissive peptides. YIGSR a pentapeptide of laminin has 
been found to enhance neuronal adhesion. The YIGSR modified alginate graft was made 
in the form of strings so that it could act as a bridge at the site of injury. Rat abdominal 
fibroblasts were genetically engineered by ex vivo gene therapy to secrete human brain 
derived nerve growth factor (BDNF) that would enhance neuronal growth. These cells 
were incorporated in the modified alginate solution before they were made into strings, 
and the strings were then coated with a high molecular weight polyamine.  This 
polyamine coating would prevent high molecular weight immunoglobulins like IgG from 
entering the graft interacting with the fibroblasts while allowing the lower molecular 
weight BDNF to escape to the outside. This graft could then be frozen and stored under 
liquid nitrogen and thawed when needed, and placed at the injury site without immune 
suppression. 
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1. INTRODUCTION 
1.1 Treatment of Spinal Cord Injury 
Spinal cord injury (SCI) affects nearly 200,000 people in the United States and 
approximately 11,000 people sustain new spinal injuries every year1. Most SCIs are 
incurred as a result of auto accidents, sports injuries, falls or industrial mishaps1. 
Nearly 60% of those affected are 30 years or younger and are mostly men. SCI has a 
tremendous impact on a person, physically, emotionally and socially. Following 
spinal cord injury there is disruption of communication between the brain and other 
parts of the body, and messages are no longer transmitted across the injured area2. 
SCI can occur at any level and the bodily functions that may be lost or altered 
depend on the level of injury. The higher the injury, the more movement and 
sensation will be lost or altered. An injury at the cervical (neck) level may cause 
paralysis of both arms and legs resulting in quadriplegia, while lower injuries like 
those at the thoracic (upper-back) level may affect only the lower part of the body 
causing paraplegia. Injuries are also classified as complete or incomplete depending 
on whether there is total or partial loss of sensation and movement below the level 
of injury. SCI can also result in loss of bowel and bladder control. This type of 
debilitating injury requires lifelong care and rehabilitation at a cost of about 1 
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million dollars in the case of quadriplegics1.  
The reason central nervous system (CNS) neurons do not regenerate following 
an injury may be due to the poor intrinsic regenerative ability of the neurons 
themselves, presence of a glial scar and circulating macrophages and proteoglycans3. 
Various strategies have been tried to aid in neuronal regeneration following injury, 
some of them being peripheral nerve transplantation, stem cell transplantation, 
provision of guidance channels, release of neurotrophic factors via ex vivo gene 
therapy, etc. While several of these strategies have shown positive results the 
general consensus would be for developing a treatment method that would combine 
many of the above mentioned strategies to obtained the desired results.  
1.2 Ex Vivo Gene Therapy in Spinal Cord Injury Treatment 
Neurotrophic factors are known to prevent neuronal death as well as enhance 
axonal regeneration following injury4. Direct application of neurotrophic factors at 
the site of injury is not very effective since multiple doses would be required 
leading to repeated invasive procedures. Systemic administration would also be 
ineffective since the neurotrophic factors would not cross the blood brain barrier 
and ultimately not reach the target site. Ex vivo gene therapy would help to 
circumnavigate these problems and deliver the factors at the injury site in an 
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effective manner. Ex vivo gene therapy involves transplanting cells that have been 
genetically engineered to release neurotrophic factors, at the site of injury. In an 
ideal situation the patients own cells would be used for the ex vivo gene therapy to 
prevent graft rejection by the host immune system, but this process would not only 
be expensive but also time consuming. Since treatment needs to be available shortly 
following injury to enhance nerve regeneration non-autologous grafts have been 
developed. Cell lines have been developed that were modified to express different 
neurotrophic factors, and stored so they would be readily available5, 6. 
Transplantation of non-autologous cells would require the patient to be under 
immune suppressive therapy in order to avoid graft rejection by the immune system, 
which in turn would lead to complications such as infections. This would lead to the 
graft being less or non effective. These modified cells could be protected from the 
host immune system by encapsulating them in a polymer matrix such as collagen7, 
Matrigel8 and alginate9. 
1.3 Alginate 
Alginate is a polysaccharide obtained from brown sea weed10. It contains β-(1-
4)-linked D-mannuronic acid (M) and α-(1-4)-linked L-guluronic acid (G) residues. 
Alginate is therefore a polymer that is linear and unbranched. The D- mannuronate 
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chain forms a 3-fold-left handed helix with weak intramolecular hydrogen bonding 
between the hydroxyl group in position 3 and the following oxygen ring11. Alginate 
forms gels with divalent cations like calcium, barium, etc and certain trivalent 
cations like iron and aluminium, via inter-chain cross linking of the carboxylate 
groups on the guluronate units. The properties of the gel are governed by the 
sequence and composition of the monomer chains. The greater the content of G 
monomers the stronger is the gel formed. Alginate hydrogels can be prepared by 
adding a solution of sodium alginate to a cation solution which causes the 
crosslinking. Alginate belongs to a group of compounds that have been generally 
regarded as safe by the FDA. It has also been used in tissue engineering for cell 
encapsulation and various other functions9, 12. Alginate hydrogels can also be coated 
with poly cations such as poly-L-ornithine which acts as a semipermeable 
membrane regulating the substances that go in and out of the hydrogel. Thus this 
coating can prevent the immunoglobulins of the host from affecting the 
encapsulated cells and also allow the diffusion of the neurotrophic factors released 
from the cells. Thus immune suppression of the host and its complications can be 
avoided. Alginate can also be modified with specific peptides that would further 
make the surface of the hydrogel favourable for cell adhesion and regeneration9. 
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1.4 Statement of the Problem 
The aim of this thesis is to develop a graft that could be implanted in the spinal 
cord following spinal cord injury (SCI) that would aid neuronal regeneration. The 
goal is to provide a surface that supports neuronal cell adhesion and promotes 
neuronal regeneration. The alginate graft should act as a bridge at the site of the 
injury and provide an environment that is favorable for cell adhesion and growth. 
The graft should be stable and in a size range that is compatible for grafting in the 
spinal cord. The graft should be non-toxic and safe for human transplant. The graft 
should be stable in the body over a period of time for it to act as bridge in neuronal 
regeneration. The method used for developing this graft should be repeatable. The 
specific goals of this thesis were: 
1. To develop a method for fabricating alginate hydrogel strings. The aim is to 
develop alginate strings that would acts as a bridge across the site of spinal injury 
and would be stable. 
2. To modify the surface of the alginate strings with growth permissive peptides. 
The aim was to develop a graft whose surface would promote neuronal cell 
adhesion and regeneration. Use in vitro techniques to determine the effect of 
peptide modification of alginate on neuronal cell adhesion and growth. 
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3. To determine the effect of peptide type and concentration on neuronal cell 
adhesion. The aim was to modify alginate with different concentrations of 
specific peptides and determine in vitro the optimum concentration of peptide 
modification that ensures neuronal cell adhesion. 
4. To develop a method to encapsulate genetically engineered cells in the strings. 
The aim is to encapsulate genetically engineered cells that secrete neurotrophic 
factors in the strings. The object was to determine the effect of encapsulation on 
cell survival. 
5.  To test in vitro transgene expression using specific staining kits. The aim is test    
transgene expression by the cells encapsulated in the alginate strings and also 
study in vitro, the effect of the neurotrophic factors on nerve cell growth and 
differentiation. 
6. To develop a method to store the alginate strings for immediate use. The aim was 
to freeze and reconstitute the alginate strings with the modified cells. This can be 
tested in vitro by freezing and thawing the strings containing the modified cells 
and checking for cell survival and transgene expression. 
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2. BACKGROUND AND LITERATURE REVIEW 
2.1 Spinal Cord Injury 
Spinal cord injury (SCI) affects nearly 200,000 people in the United States and 
approximately 11,000 people sustain new spinal injuries every year. Most SCI’s are 
incurred as a result of auto accidents, sports injuries, falls or industrial mishaps1. 
Mostly occurs in young adults particularly males as a part of sports injury, 
automobile accidents, etc. SCI has a tremendous impact on a person, physically, 
emotionally and socially. Following spinal cord injury there is disruption of 
communication between the brain and other parts of the body, and messages are no 
longer transmitted across the injured area2. The extent of disruption in 
communication depends upon the severity and the level of the injury. The human 
spinal cord is a bundle of nerves about a foot and a half long, and extends from the 
brain to the lower back. The spinal cord acts in relaying messages from the brain to 
the other parts of the body and also receives information from all over the body 
which is in turn transmitted back the brain. Since nerve fibers are very sensitive they 
are protected by the backbone which consists of 33 vertebrae which are classified 
into 5 regions13. 
Following trauma there is axonal injury leading to death of disconnected 
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neurites and vascular damage leading to hypoxia. The inflammatory response 
following injury leads to the appearance of macrophages at the site which in turn 
contribute to the scar formation14. The scar formation by the macrophages, 
astrocytes and microglia is a result of the body re-establishing the blood brain 
barrier thereby preventing further injury to the CNS15. The cells and connective 
tissue that make up the scar have been found to release both growth promoting and 
inhibiting molecules. Regeneration of central nervous system neurons basically 
depends on the severity of the injury to the neurons. If the somata of the neurons are 
involved in the lesion then the neurons die immediately. If the injury is only an 
axotomy, transection or severing of an axon, without injury to the soma the cells 
would die by apoptosis days or weeks after the injury16. Once the distal nerve 
segments are separated from their cell bodies they start to degrade and are taken up 
by macrophages over a period of time (Wallerian degeneration)17. Degeneration of 
the axon causes loss of contact with the surrounding astrocytes and 
oligodendrocytes leading to loss of functions that are dependent on the activity of 
the neurons. To combat this, the neurons try to grow into the lesion but this process 
is abrupt and there are no lengthy neurites that bridge the lesion. This is due to the 
retraction of the growth cones when they come in contact with the injury and also 
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due to myelin removal.  
Earlier it was believed that CNS neurons lacked the ability to regenerate. 
Recent research has shown that the CNS neurons do have the ability to regenerate, 
but the ability of the neurons to regenerate, bridge the lesion and regain their 
functionality depends on various factors. The rate of regeneration not only varies 
between different CNS neurons but also within different branches of the same 
neuron. Supply of neurotrophic factors plays a vital role in neuronal regeneration. 
Following CNS neuronal injury there is the presence of neurotrophic factors, which 
are essential for the survival of the axotomized neurons. The percentage of surviving 
axotomized neurons is reduced by about 30% within the first 7 days, or even to 50% 
if there is circulating antibodies to brain derived nerve growth factor (BDNF) 18. 
Experiments performed by Giehl et al18 have demonstrated that infusion of BDNF 
directly into the cortex can help to save these axotomized neurons showing that 
there is a lack of endogenous trophic factors for the axotomized corticospinal 
neurons. Therefore BDNF along with other neurotrophic factors plays a vital role in 
neuronal regeneration. 
Axonal regeneration is also dependant on regeneration associated genes 
(RAGs). Total axonal growth following regeneration depends on the level as well as 
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the types of RAGs expressed and also on the axonal environment. Following injury 
to CNS neurons expression of RAGs remains unchanged in most of the dorsal root 
ganglia (DRG). One of the RAGs, Growth associated protein-43 (GAP-43), is 
important in axonal sprouting19. DRG neurons that express high levels of GAP-43 
tend to grow several mm/day provided they have a growth permissive environment, 
but most DRG neurons following injury express very low levels of GAP-43 leading 
to a slow rate of axonal regeneration. 
Another factor that regulates axonal regeneration is the extracellular matrix 
(ECM). ECM molecules like laminin, fibronectin, proteoglycans, collagen, etc. play 
an important role in neurite outgrowth. In the CNS these ECM molecules are 
synthesized by the astrocytes. Laminin is a promoter of neurite outgrowth whereas 
proteoglycans inhibit them. Laminin is a 900kDa complex extracellular protein; 
composed of three different polypeptide chains termed α, β and γ. These chains are 
linked together in various combinations to form 15 known isoforms or types of 
laminin. Each isoform has distinct characteristics and functions. Isoforms are known 
to change in normal tissues at various stages of development but they also have been 
found to shift in the presence of several invasive cancers. Quantitatively it is one of 
the most abundant glycoprotiens present in the basement membrane. It helps in 
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modulating several key biological activities including cell adhesion, migration, cell 
survival and gene expression20, 21. Variability in the spatial and temporal expression 
of laminins suggests that different laminins perform distinct functions. The 
expression levels of the extracellular matrix (ECM) glycoprotein laminin-1 are high 
along axonal tracts in the developing cerebellum, suggesting that laminin-1 plays a 
major role in cerebellar granule cell pathfinding. Laminin-1 has been found to be 
one of the key molecules in the CNS following injury22. 
2.2 Strategies in Treating Spinal Cord Injury 
Various strategies have been used to treat spinal cord injuries and several 
different approaches are also currently being tested in vitro and in animal spinal 
injury models. Some of the strategies that are currently being explored include 
grafting of peripheral nerves to the lesion, providing growth factors, stem cell 
transplants, supplying antibodies to growth inhibiting molecules, guidance channels 
like collagen tubes, ex vivo gene therapy with encapsulated cells and combination 
therapies. Some of these strategies are discussed below. 
2.2.1 Cell Grafting 
 The axons in the peripheral nervous system, just like the CNS, regenerate 
only if their cell bodies are intact. Shortly after axonal injury there is cell body 
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swelling which is followed by Wallerian degeneration where the distal portion of 
the axons and myelin sheath start to degrade. Finally the intact neurolemma cells 
divide and regeneration tubes are formed through which new axons and eventually 
myelin will reform. Axotomized neurons start to express growth associated proteins 
like GAP-43, cytokines and other neuropeptides. Schwann cells, whose primary 
function is myelination of axons, start expressing cell adhesion molecules and 
extracellular matrix proteins that would aid in axonal regeneration23. Since 
Schwann cells act as guidance channels for regenerating axons in the PNS they 
were transplanted in the CNS to verify if they had the same effect. Trials with 
injections of cultured Schwann cells or grafts containing Schwann cells in injured 
spinal cord have shown increase in axonal sprouting24. If Schwann cells are 
transplanted immediately following spinal injury they survive better and transected 
axons are seen growing into the guidance channels25. Though there was axonal 
sprouting only a small percentage (1%) were found to enter the host tissue. 
Transplants of embryonic rat brain and spinal cord tissue have been shown to 
survive and differentiate in damaged adult rat spinal cords26. Transplantation of an 
intact brain stem provides a source of neurotransmitters like serotonin or nor-
adrenaline for the denervated spinal cord and they can also act as a bridge for the 
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regenerating axons to grow along27. The fetal grafts also provide neurons onto 
which the host axons can synapse, a process that would help relay neural signals 
and the graft may also provide glial cells that would aid in remyelinating the 
damaged axons. Transplantation of fetal neural tissue in the adult spinal cord has 
been less successful than in the neonatal spinal cord. It has been found that though 
the host neurons synapse with the graft, they fail to project through the lesion and 
the donor neurons also extend from the graft for only a few millimeters28. Injured 
adult neurons may require neurotrophic factors in addition to the graft to aid in 
regeneration. 
  Olfactory neurons are the only kind of neurons that are produced and continue 
to divide throughout adult life29. The olfactory ensheathing cells (OECs) are 
specialized glial cells that encourage the growth of axons from the mucosa and they 
possess the characteristics of both Schwann cells as well as astrocytes. Unlike the 
Schwann cells that are confined to the PNS where these OECs accompany the 
olfactory axons to the CNS and provide guidance for the axons to their correct 
positions in the olfactory glomerulus. These are the only glial cells that have the 
capacity to cross the PNS-CNS boundary and can also myelinate axons in vitro30. It 
was found that grafting of the olfactory ensheathing cells resulted in axons growing 
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through the lesion, and continued regeneration through the denervated region. The 
olfactory cells also caused the myelination of both individual as well as groups of 
axons forming fascicles31. The advantage of this type of treatment would be that 
cells from the patient’s own olfactory mucosa could be cultured, thereby 
circumventing the problems of graft rejection and immune suppression. The 
limiting factor of this kind of therapy would be that the graft would not be readily 
available following injury. 
Another kind of cell line that has been under study for grafting to combat 
spinal cord injury is the embryonic stem cells. The reason that stem cells are 
attractive for grafting is that they are totipotent cells and can be made to 
differentiate into any phenotype with the addition of specific differentiating factors. 
These cells can also be maintained in culture and used as a source of neural cells32. 
In 1993 Pleasure et al implanted neurons, prepared from NT2N cell line by treating 
them with retinoic acid, into the spinal cord of mice32. The neurons not only 
survived in the host for a prolonged period of time but also managed to mature and 
show neurite outgrowth. This approach could be promising in treating spinal injury 
since these cells are readily available for grafting33. 
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2.2.2 Antibodies to Growth Inhibiting Molecules 
Following injury oligodendrocytes and astrocytes are present as a result of the 
inflammatory response. Both these cell types have growth inhibitory molecules for 
axons and axons can only regenerate if they either have no receptors to these 
inhibitory molecules or if they can bypass the signals released from them. 
Embryonic neurons are able to grow over oligodendrocytes while mature sensory 
axons show an increase in the calcium level in their growth cones leading to their 
collapse. Astrocytes produce proteoglycans that inhibit neuronal regeneration by 
blocking the growth promoting characteristics of laminin and other ECM 
molecules34. Inhibiting factors released by oligodendrocytes and myelin can be 
combated using antibody IN-1, which has proven effective in vitro35 and also when 
used in adult rat spinal injury models36.  
Astrocytes produce proteoglycans that are inhibitory to the growth promoting 
effects of laminin and other basement membrane molecules. The enzyme that has 
been shown to be efficient against the proteoglycan mediated inhibition is bacterial 
Chondroitinase ABC. This enzyme acts by cleaving the glycosaminoglycan (GAG) 
side chains on the chondroitin sulfate proteoglycans (CSPGs)37. This enzyme 
however does not fully digest the GAG chains leaving behind side chains which, 
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even though they are less inhibitory than entire GAG chains, reduce the axonal 
regeneration capacity38. Currently research is being done on an improved target 
specific enzyme Xylosyltransferase-1 that acts on the m-RNA of the enzyme that 
initiates the GAG formation on the CSPGs39. Combining neurotrophic factors with 
these enzymes would help to enhance axonal regeneration. 
2.2.3 Neurotrophic Factors 
Neurotrophic factors are growth factors produced mainly in the embryonic 
stage in humans, to aid in the growth and development of the CNS. These factors 
are not generally produced during adult life unless there is an injury to the CNS. 
Studies were performed on the nerve growth factor (NGF) by Scott D Jr et al as 
early as 196340.  Further studies have shown that there are growth factors other 
than NGF like neurotrophin-3 (NT-3), brain derived nerve growth factor (BDNF), 
glial cell derived nerve growth factor (GDNF) and ciliary neurotrophic factor 
(CNTF). Studies using these nerve growth factors to treat adult rat spinal cord injury, 
either singly or in combination, have shown that they not only help to prevent 
atrophy of neurons but also help in their regeneration41, 42, and 43. Since these factors 
do not cross the blood brain barrier they have to be administered locally rather than 
systemically. The problem with local administration of these factors would be that 
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repeated invasive techniques have to be employed and this problem can be 
overcome by the local transplantation of cells that are genetically engineered to 
release specific nerve growth factors. 
2.2.4 Nerve Guidance Channels 
The aforementioned studies show that the CNS neurons have the capacity to 
regenerate if the environment can be made growth permissive. Even though these 
studies have proved that axons can sprout into the lesion they are not conclusive if 
the sprouting axons would bridge the lesion and synapse with the neurons across the 
gap. For this purpose guidance channels in the form of tubes that have been used in 
peripheral nerve repair44 are also being employed in spinal cord injuries45, 46, and 47. 
The use of tubes in the repair procedure allows the regulatory factors and the cells 
from the distal stump to remain in direct contact with the site where the 
regeneration occurs. It also provides a direction for the axons crossing the gap and 
also helps to isolate the injury site from exogenous cells and tissues48. The last fact 
could be beneficial in that it would prevent the regenerating neurons from being 
exposed to macrophages and various other inhibitory factors, at the same time it 
could also prove to be detrimental by not allowing the growth factors that are 
released to reach the growing neurons. Among the different types of tubes that have 
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been employed for treating axonal regeneration in the CNS collagen tubes seem to 
be the best suited48. The advantages of using collagen are that it is non-toxic, non 
antigenic, flexible, biodegradable, permeable and also promotes regeneration49, 50. 
Studies have also show that the use of collagen tubes helps to reduce the glial 
response that occurs after injury51. 
2.2.5 Ex Vivo Gene Therapy 
     Another approach to treating spinal cord injury is to transplant cells that have 
been genetically engineered to release neurotrophic factors at the site of the lesion. 
As mentioned earlier systemic administration of neurotrophic factors is ineffective 
in treating spinal cord injury since these factors cannot cross the blood brain barrier. 
Implantation of Schwann cells that were genetically engineered to express BDNF in 
adult rat spinal injury models led to increase in neuronal regeneration across the 
complete transection8. Fibroblasts are the most commonly used cell lines for such 
modifications since they can be harvested easily and are also a robust cell line that is 
easy to culture. Transplantation of primary rat fibroblasts, which were modified to 
express NGF, into adult rats with spinal injury led to survival and regeneration of 
sensory, motor and nor-adrenergic neurites5. Transplantation of fibroblasts that 
express neurotrophin-3 (NT-3) in adult rats with dorsal cord lesion led to partial 
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functional recovery52. These genetically engineered cells have also been found to 
promote neuronal regeneration when transplanted months after injury which proves 
that they induce existing neurons to extend neurites into the lesion. This approach 
could be employed to modify cells to express other neurotrophic factors like BDNF, 
ciliary neurotrophic factor (CNTF) and glial cell line derived neurotrophic factor 
(GDNF). Primary rat abdominal skin fibroblasts that were genetically modified to 
release BDNF were transplanted into adult Sprague Dawley rats with partial cervical 
hemisection2. The result was rubrospinal tract regeneration that was observed for a 
period of up to 2 months after lesion and transplantation. The study also showed that 
several neurons showed sprouting into the graft and beyond, into the lesioned area 
and spinal segments. Behavioral studies performed on these animals also showed 
that they had significant recovery of forelimb function in the presence of the BDNF 
secreting fibroblast graft9. Similar studies have been conducted using neuronal stem 
cells that have been genetically modified to express NT-3 in spinal cord injury 
repair53. This test showed that the neuronal stem cells not only survived but also 
produced NT-3 in adult rat spinal cords. These stem cells also differentiated into 
neuronal and glial cells and migrated in the cord for long distances. For application 
in humans the hosts own cells could be genetically modified to express the desired 
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neurotrophic factor. This however would not be feasible if the graft had to be 
applied immediately following injury. In such situations ready made non-autologous 
(allografts) grafts have to be employed. Grafting cells that are foreign to the host 
however might lead to strong host immune reaction warranting the need for a rigid 
immune suppressive protocol. Such an immune suppressive therapy not only makes 
the host susceptible to various infections but could also reduce the effectiveness of 
the graft. The way to circumvent this problem would be to encapsulate these 
genetically modified cells in a selectively permeable matrix, which would allow the 
diffusion of the growth factors and waste products out of the graft and cell nutrients 
into the matrix meanwhile preventing the host immune cells from entering it. 
Matrices like Matrigel8 and collagen54 and 55 have been used in embedding Schwann 
cells and fibroblasts modified to express NGF respectively and then transplanting 
them in the spinal cord lesion. Some other materials that have been used to 
encapsulate these genetically engineered fibroblasts include acrylonitrile-vinyl56 
chloride and polyethersulfone57 hollow fibers that are then transplanted in the spinal 
cord. Polypropylene fibers with fibroblasts genetically modified to express CNTF 
when transplanted subcutaneously in mice resulted in slowing down progressive 
motor neuropathy58. Above mentioned studies show that encapsulating and grafting 
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genetically engineered cells can aid in neuron survival and growth following injury. 
They also provide the means by which cells that are genetically modified to express 
different neurotrophic factors can be encapsulated together in matrices and even 
encapsulating antibodies to growth inhibitors or a combination of both. The success 
of this kind of therapy however would depend on cell survival within the matrix and 
the expression of the desired neurotrophic factors or antibodies to growth inhibitors 
into the lesion both in vitro and in vivo. The matrix should also provide the 
necessary protection for these modified cells from the host immune system. The 
matrix should also be made from materials that are non toxic to the host. A material 
that would fulfill the above criteria would be alginate and it also uses mild 
conditions for encapsulation.  
2.3 Alginate 
Alginate is a linear polysaccharide derived from brown seaweed. It is a water 
soluble copolymer consisting of 2 monomeric units of 1-4 linked α-L-guluronic and 
β-D-mannuronic acid residues. Alginate is a hydrated polyelectrolyte in solution 
and occurs in a ribbon conformation59. The structure of alginate has been studied in 
detail using X-ray diffraction and infrared spectroscopy. 
The D- mannuronate chain forms a 3-fold-left handed helix with weak 
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intramolecular hydrogen bonding between the hydroxyl group in position 3 and the 
following oxygen ring60. The L- guluronate on the other hand forms stronger 2-fold 
screw-helical chains by intramolecular hydrogen bonding between the carboxyl 
group and the stronger hydroxyl group in position 2 of the previous residues, and 
the weaker hydroxyl group in position 3. Alternating poly α-(1-4)-linked L-
guluronate- β-(1-4)-linked D-mannuronate contains both equatorial-axial and axial-
equatorial links and forms a disorderly conformation. They have hydrogen bonds 
between the carboxyl group on the mannuronate and the hydroxyl groups in the 2 
and 3 positions of the subsequent guluronate. The free carboxylic acid groups have 
a water molecule bound to the carboxylate by a hydrogen bond. These acid residues 
may be present in varying proportions depending on the source of the alginate; they 
may be polyguluronic blocks (GG), polymannuronic (MM) or mixed (MG) as 
shown in table 2.3.1. 
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Table 2.3.1 Composition of Alginates Obtained from Various Species of Kelp 
(from reference 59) 
 
Species M Content (%) G Content (%) M/G Ratio 
Ascophyllum nodosum     65     35    1.85 
Ecklonia cava     62     38    1.6 
Eisenia bicyclis     62     38    1.6 
Macrocytis pyrifera     61     39    1.56 
Laminaria digitata     59     41    1.45 
Laminaria hyperborean     31     69    0.45 
 
  Calcium ions can replace the water molecules bound to the carboxyl groups 
thereby resulting in the closure of the guluronate chains but not the mannuronate, 
which results in an egg box like conformation61 and 62. The chains are stabilized by 
hydrogen bonding between the other carboxylate oxygen and the hydroxyl group in 
position 2 of the subsequent residues. 
Alginate thus forms gels with multivalent cations like calcium and aluminium 
and the properties of the gel are governed by the sequence and composition of the 
monomer chains and the cross linking ion. The greater the content of G monomers  
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Figure 2.3.2: Chemical Structure of the Mannuronic and Guluronic 
Acid Groups of Alginate (from ref. 59) 
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the stronger is the gel formed. These gels are similar to alginate. This property of 
alginate to gel in the presence of a polycation solution (aluminium63, zinc64, calcium, 
and barium65) has made it possible for it to be used as a drug delivery agent. The 
mechanical rigidity of the alginate hydrogels depends on the affinity of the cations 
to alginate61. Studies have shown that the chemical structure, molecular size, and gel 
forming kinetics of the hydrogel play an important role in its properties including 
swelling, stability, biodegradability, immunological characteristics, and 
biocompatibility35.  
Alginate is biocompatible and is harmless to the body65, 66. It is used in the 
food industry as a thickener, emulsifier and as a stabilizer. Alginate belongs to a 
group of compounds that have been generally regarded as safe by the FDA. It has 
also been used in tissue engineering for cell encapsulation and various other 
functions61. The pore size of alginate hydrogels formed by crosslinking varies over 
a wide range. Large proteins like fibrinogen could easily diffuse out of calcium 
alginate hydrogels in their entirity67. Only cells and certain high molecular weight 
enzymes could be completely immobilized in alginate hydrogels68 like islet cells, 
catalaze, etc. 
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2.3.1 Alginate for Cell Encapsulation 
 Alginate hydrogels are produced by introducing alginate into an aqueous 
solution of multivalent cations in and mild environment using non-toxic reactants. 
Since alginate hydrogels are easy to make and safe they have been studied 
thoroughly for drug delivery and also believed to be the material of choice for cell 
encapsulation. The protein release from the hydrogel can be controlled by changing 
the properties of the hydrogel like varying the concentration of alginate used or 
changing the crosslinking ion69. The rate of release of the drug can also be 
controlled by coating the hydrogel with polypeptides such as poly-L-ornithine and 
poly-L-lysine. These polypeptide coatings not only influence the rate of drug 
release but could also be made to be size selective. In cases where these hydrogels 
are used for cell encapsulation, the polypeptide coating could act as a barrier against 
the host immune systems. This can be achieved by varying the molecular weight of 
the polypeptide in such a manner that it would exclude the immune components but 
still permit the release of the therapeutic compounds thereby avoiding the need for 
immune suppressive therapy that would be mandatory following autologous grafts. 
Studies have been conducted where pancreatic islets cells have been 
encapsulated in alginate and transplanted in rats70. Following this study various  
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Figure 2.3.4: Alginate Egg Box Model on Cross Linking with 
Calcium Ions (from ref. 60)  
other studies were done in which different cell types like hybridoma cells71, 
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hepatocytes72, renal cells73 and genetically engineered fibroblasts9 were used for the 
delivery of a wide range of compounds like hormones74 and 75, antibodies71, 
angiogenesis inhibitors76 and neurotrophic factors9. Alginate hydrogels have also 
been used to treat wounds77 and in tissue repair78. 
2.3.2 Biocompatibility of Alginate 
 Alginate falls under the category of products that the food and drug 
administration (FDA) has generally regarded as safe (GRAS). Alginate is currently 
being used in the food industry as a stabilizer and a thickener. Several studies have 
also been done where alginate was administered orally to rats and dogs at varying 
dosages and for different durations and no mortalities or ill effects were observed59. 
In vitro studies where alginate has been introduced in cell cultures show that there is 
very minimal cytotoxicity and alginate is also tolerated in animals when 
administered orally at a dosage of 500mg/Kg79. While most studies show that 
alginate is non-toxic when used in vivo some studies show that the body may 
produce foreign body reaction to alginate. The foreign body reaction would result in 
fibrosis around the hydrogel graft which would then be followed by necrosis 
ultimately reducing or nullifying the effect of the graft80. Studies done to elucidate 
the reasons behind this reaction reveal that the mannuronic acid residues may be 
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responsible for the foreign body reaction, while other studies show that the 
guluronic acid residues may induce the necrosis80. This type of reaction may be the 
result of contaminants that are found in crude alginate which was used in the above 
mentioned study. Alginate can be purified by repeated filtration and precipitation 
procedures that would help to remove the contaminants and make the alginate 
biocompatible81 and 82. Though the purification helped to prevent fibrosis the lifetime 
of these grafts ranged from 6 to 20 weeks which was similar to the grafts made of 
crude alginate. Thus purification of alginate could help in increasing the 
biocompatibility of the alginate grafts83 and 84. 
2.3.3 Hydrogel Properties and Shapes 
The important advantage of using hydrogels for grafts is that they can be 
made to specific shapes and dimensions according to the need. Alginate has been 
used in various forms such as hydrogel blocks, spheres, microcapsules, etc. The type, 
shape and the dimensions of these hydrogels have an effect on the release of the 
therapeutic compounds entrapped in them. Selection of the appropriate hydrogel 
scaffold material depends on the physical properties, mass transport property and the 
biological interactions it would have. These design variables are governed by the 
particular application they are going to be used for and the environment into which 
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they would be introduced. 
2.3.3.1 Physical Properties 
Most scaffolds employed in tissue engineering usually fill a space that is 
normally occupied by host tissue and act as a framework over which cells could lay 
down and regenerate into tissue. The mechanism by which gels form dictates the 
way molecules and cells are incorporated and ultimately their delivery from the 
scaffold. Once these hydrogel grafts are placed the tissue regeneration would depend 
on the mechanical properties of the graft. The graft should not only be able to 
withstand load but also be able to distribute it thereby providing the stability the 
cells would require to grow on. For alginate these properties would depend on the 
polymer composition, crosslinking and gelling conditions such as temperature and 
pH. The mechanical strength and compression of alginate could be increased by 
increasing the ratio of G to M or by increasing the length of the G blocks85. The 
mechanical strength of ionically crosslinked alginate would increase with the 
increase in the ion concentration and when divalent cations with higher affinity to 
alginate are employed86. Over time these hydrogels may undergo degradation and 
dissolution unless the tissue grows into these grafts and helps to strengthen them87. 
The desired rate of degradation of hydrogels depends on the application that it 
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would be employed for. In tissue engineering however the ideal rate of hydrogel 
degradation would match the rate of tissue regeneration. Ionically crosslinked 
alginate usually undergoes dissolution which would depend on the ionic 
concentration of the environment that it would be place in.  
2.3.3.2 Mass Transport Properties 
The successes of these hydrogels in tissue engineering applications depends on 
the appropriate transport of gases, nutrients, cells, waste products, etc. into and out 
of the scaffolds. Gel properties such as polymer type, polymer size and 
concentration of the crosslinker ion help to determine the porous nature of the gel88. 
As a result the rate of diffusion into and out of the hydrogels would depend on the 
size and molecular weight of the particles compared to the pores in the hydrogels. 
The diffusion of high molecular weight compounds from alginate hydrogels are 
decreased by increase in the concentration of alginate or increasing the 
concentration of the crosslinking Ca2+ ions. For alginate hydrogels the diffusion of 
charged molecules would also depend on their interactions with the negatively 
charged alginate chains89. Enhancing the delivery of oxygen and nutrients and 
removal of waste products is essential for hydrogels with cells immobilized in them. 
In vivo most cells exist within 100µm of a capillary and diffusion can occur freely 
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within this distance to ensure cell and tissue survival13. So cells need to be 
immobilized in grafts of small size whereby the cells entrapped are in close 
proximity to nutrients that would ensure their survival. 
2.3.3.3 Biological Properties 
Hydrogels that have been designed for grafting in the body must promote 
desirable cellular functions and tissue functions without eliciting a chronic 
inflammatory response. As far as alginate hydrogels are concerned the extent of the 
inflammatory response depends on the purity of the commercially available alginate. 
Though purified alginate is nontoxic it does not possess any inherent cell adhesive 
properties. Cells do not have receptors to most hydrogel forming polymers, with the 
exception of collagen which is an ECM protein, and therefore cells cannot adhere to 
them. Since hydrogels are hydrophilic, ECM proteins do not easily adsorb onto their 
surface90. The best way to modify hydrogel surfaces to present specific cell adhesive 
receptors could be achieved by covalently coupling an entire ECM protein91 or a 
peptide sequence to the polymer92 and 93. The most commonly used peptide sequence 
for this approach would be the Arginine – Glycine - Aspartic acid - Serine (RGDS)94 
sequence that can be derived from ECM proteins such as laminin, fibronectin, 
collagen, etc. RGDS peptide however is not specific for nerve cell adhesion. So 
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other peptides are commonly employed for this purpose which include, Tyrosine – 
Isoleucine – Glycine – Serine – Arginine (YIGSR from laminin)95 and Isoleucine – 
Lysine – Valine –Alanine – Valine (IKVAV also from laminin)96. Various studies 
have been done to prove that the above mentioned peptides could be covalently 
coupled with alginate and have been found to promote nerve cell adhesion. Peptide 
modification helps to create analogs of protein modified surfaces also allowing the 
control of concentration and orientation of the peptides on the hydrogel surface. 
Studies have shown that YIGSR and IKVAV promote a greater number of neurites 
per cell97. Experiments have also shown that YIGSR and IKVAV modified surfaces 
selectively promote neuronal cell adhesion98.  
The hydrogels can also be molded to different shapes according to the 
application. Alginate hydrogels have been molded into different shapes like beads, 
blocks, films, fibers, etc. for various applications. Macro and micro alginate beads 
have been employed in delivery of therapeutic drugs such as insulin99, melatonin64, 
etc. Alginate beads also happen to be the vehicle of choice for grafting live cells that 
would have a therapeutic effect. Some of the common cell lines that have been 
immobilized in alginate beads are islet cells65, hepatocytes73, genetically engineered 
fibroblasts9, etc. Alginate blocks with TNF-β1 incorporated in them have been 
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studied for treating intracranial aneurysms100. Alginate films have been tested for 
use as biodegradable packaging film for disposing waste products101. Alginate films 
have also been studied for delivery of therapeutic drugs like acetaminophen102. 
Alginate fibers can be produced by extruding alginate solution into a calcium ion 
bath and then letting the fibers dry. These fibers could then be collected on spools 
for knitted fabrics or chopped for use in non-woven materials. Several commercially 
available wound dressings have calcium alginate fibers103. The in-situ gelling 
property of alginate has also been utilized for certain applications like prevention of 
adhesions during tissue repair, treatment of burns, in arresting hemorrhage and 
ophthalmic drug delivery104. An oral controlled release system has also been studied 
wherein a dry mixture of sodium alginate, calcium phosphite and a soluble drug are 
compressed into tablets. When administered orally the tablet is acted upon by gastric 
juices following which the calcium ions interact with the alginate forming a sponge 
like matrix and the drug release would be dependent on the dissolution of the gel 
and diffusion of the drug from the gel105. 
 
 
3. MATERIALS AND METHODS 
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3.1 Materials 
3.1.1 Chemicals 
 Manugel DMB a high guluronic acid alginate was a generous gift from ISP 
Alginates, San Diego CA (formerly the Nutrasweet Kelco Company) was used as 
obtained. N-[2-hydroxyethylpiperazine-N’ –[2-ethanesulfonic acid] sodium salt 
(HEPES), morpholinoethanesulfonic acid sodium salt (MES), poly-L-ornithine 
(PLO, MW 15,000-30,000), calcium chloride, sodium chloride, calcium sulfate, 
sodium metaphosphate, 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC) 
and N-hydroxysulfosuccinimide sodium salt (Sulfo-NHS) were purchased from 
Sigma Chemical Co., St. Louis, MO. The pentapeptide Tyrosine-Isoleucine-Glycine-
Serine-Arginine was obtained from American Peptide Company (Sunnyvale, CA). 
Natural mouse Laminin was purchased from Invitrogen, Carlsbad, CA. 
3.1.2 Cells and Cell Culture Products 
 Rat abdominal skin fibroblasts that have been genetically engineered to 
release brain derived nerve growth factor (BDNF) were kindly provided by Dr. 
Itzhak Fisher, Drexel University College of Medicine. The mouse (NB2a) and 
human (SHSY5Y) neuroblastoma cells were kindly provided by Dr. Tom Shea, 
University of Massachusetts, MA (Lowell Campus). Fertilized white leg horn eggs 
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were purchased from Charles River Laboratories Inc., Wilmington, MA. Dulbeco’s 
modification of Eagles medium with glucose (DMEM), Ham’s F-12 medium, 0.25% 
Trypsin EDTA, L-glutamine and Hank’s balanced salt solution from Fisher 
Scientific, (Fair Lawn, NJ). Antibiotics (Penicillin 100IU/ml, Streptomycin 
50µg/ml), Dibutryl cyclic adenosine monophosphate (DbcAMP), Retinoic acid 
(RA), X- Gal Staining Kit, 0.4% Trypan blue and methylene blue were purchased 
from Sigma Chemical Co., St. Louis, MO. Fetal calf serum (FCS), and Serum 
Replacement (SR – Knockout) from Gibco BRL, Rockville, MD. 100mm 
Polystyrene culture plates and 6 well culture plates were from Falcon, Becton 
Dickinson Labware, Franklin Lakes, NJ.  
3.2 Alginate Strings 
The 1% (w/v) modified alginate solution was prepared in DI water and 
sterilized by filter through a 0.45µm Millipore filter. The solution was loaded in a 
sterile 5 ml syringe with a non-beveled 22G needle. The syringe was mounted on a 
Sage syringe pump (Orion Research Inc., Beverly, MA model 355) which was 
wiped down with alcohol and placed under UV for 15 minutes in a plasma hood, 
and the flow rate was set at 13.5ml/min or a rate of 63ml/min and diameter set at  
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Figure 3.2.1 Schematic of Setup for Preparing Alginate Strings 
Alginate Strings 
22 G Needle
Alginate Solution
Syringe 
Cation Solution 
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44mm with the Kent Genie syringe pump. The tip of the needle was dipped in a tall 
500 ml beaker containing a 1.3% CaCl2 solution. Calcium cross-linked alginate 
strings were produced that are allowed to sit in the CaCl2 solution for an hour for 
hardening and were then washed thrice with 200 ml of HEPES buffer (pH 7.35) per 
wash. A schematic of the preparation of alginate strings is shown in Figure 3.2.1. 
The strings were uniform and about 350-450µm in thickness as measured using the 
micrometer scale shown in Figures 3.2.2a and b.  
3.2.1 Coating Alginate Strings 
The strings were then coated with poly-L-ornithine, molecular weight 15,000 - 
30,000, at a concentration of 0.5mg/ml of alginate for 6 minutes under gentle 
shaking. The volume of PLO solution used was 6 times the volume of the alginate 
used for making the strings. The PLO solution was prepared in HEPES buffer just 
before its addition and was filtered using a 0.2µm sterile cellulose acetate filter into 
an autoclaved beaker. The strings were then washed 3 times with 200 ml of HEPES 
buffer to remove any unreacted PLO. The strings were then exposed with 100ml of 
1% (w/v) modified alginate solution for 15 minutes. The strings were then washed 
thrice with HEPES buffer to remove excess unreacted modified alginate. All buffer 
solutions and glassware used in the experiments were sterilized by autoclaving. 
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Figures 3.2.2a & b: Alginate Strings 
Figure a. is a light micrograph taken at a magnification of 250X shows 
a piece of alginate string with smooth regular borders. The black like 
represents a scale of 100µm. Figure b. is a light micrograph taken at a 
magnification of 100X showing a piece of alginate string on a 
micrometer scale. The black line represents a scale of 100µm. 
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3.3 Ensheathing Genetically Engineered Fibroblasts 
3.3.1 Culture of Genetically Engineered Fibroblasts 
 Adult Sprague-Dawley rats’ fibroblasts that have been genetically modified 
by a recombinant retrovirus to secrete BDNF (Fb/BDNF) were kindly provided by 
Dr. Itzhak Fisher, Drexel University College of Medicine. The retroviral vector has 
the human BDNF transgene linked to a reporter gene LacZ, which coded for the 
bacterial enzyme β- galactosidase2.  
Fb/BDNF were cultured in10cm tissue culture plates in DMEM supplemented 
with 10% FBS at 37°C and 5% CO2. The cells were passaged when they attained 
70-80% confluency and it has been shown that the cells express the transgene to a 
good level upto about 25 passages. 
3.3.2 Ensheathing Fb/BDNF in Alginate Strings 
Cells were harvested at about 80% confluency using 0.25% (w/v) Trypsin 
(3ml/plate for 3 minutes incubated at 37C) which helps to break the cells off the 
surface of the culture plate by enzymatic action. Once the cells were removed they 
were suspended in 0.9% sterile saline solution. A stock solution of 1.5% (w/v) 
alginate (Manugel DMB) was sterilized using a 0.45µm bottle top filter. The cells 
that were suspended in sterile saline were added to the sterile alginate solution to 
 
 42
obtain a 1% (w/v) alginate solution with a cell concentration of about 3 x 106 
cells/ml of alginate solution. Alginate strings containing the Fb/BDNF were then 
prepared by the same method as explained in section 3.2. All needles beakers and 
solutions used were sterilized by autoclaving at a temperature of 132C for 30 
minutes in a Brinkmann autoclave. Once the strings were made they were coated 
using the procedure described in section 3.2.2. The entire procedure involved in 
making and coating the alginate strings was performed under a laminar flow hood 
observing strict sterile policies. The strings were then transferred to 10cm sterile 
culture plates containing fibroblast growth medium and placed in an incubator at 
37°C under 5% CO2. 
3.4 In vitro Evaluation of Fb/BDNF in Alginate Strings 
3.4.1 X-Gal Staining for Ensheathed Cells In vitro 
 After strings with Fb/BDNF have been in culture for 7 days, they were 
evaluated for the expression of the β-galactosidase reporter gene using X-Gal 
histochemistry105. Strings made from 1ml of alginate containing Fb/BDNF were 
fixed with 0.5% (w/v) gluteraldehyde solution (1ml/ ml of alginate strings) for 
10 minutes and washed thrice with PBS. The strings were then incubated with 
X-Gal reagent (5-bromo-4chloro-3-indolyl β-D-galactopyranoside) at a 
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concentration of 1mg/mland X-Gal mixer in PBS (2ml/well) overnight at 37°C. 
The X-Gal mixer is made up of 35mM K3Fe(CN)6, 35mM. K4Fe(CN)6.3H2o, 
2mM Mg Cl2. The following day the strings in the culture plate were observed 
using a light microscope and photographs were taken using an Olympus DP-11 
digital camera. 
3.4.2 Freezing and Thawing Alginate Strings with Fb/BDNF 
Strings containing Fb/ BDNF made from equal volumes of alginate were 
placed in cryovials containing freezing medium (60%DMEM + 30% FBS + 10% 
dimethyl sulfoxide). The vials were placed in a time delayed freezing container 
(Nalgene, Fisher Scientific, Fair Lawn, NJ). under -85°C for 24 hours and then 
transferred to liquid nitrogen. Strings with the Fb/BDNF that were frozen were 
removed at different time intervals and thawed by placing them in a 37°C water bath. 
The thawed strings were then transferred to a 10cm culture plates and resuspended 
in 10ml of pre-warmed fibroblast growth medium and incubated at 37°C for 2-4 
hours. The medium was again replaced to remove dimethyl sulfoxide (DMSO). The 
strings were then dissolved in 10% (w/v) ethylene diamine tetra acetic acid (EDTA) 
and the cells were resuspended in fibroblast growth medium and pelleted by 
centrifugation at 1000 rpm’s for 5 minutes. The cells were stained using methylene 
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blue (nucleic acid stain) and the viable cells were counted using a haemocytometer, 
to verify cell survival following prolonged freezing. The cells were also plated in 
culture plates with medium to verify growth and stained with X-Gal staining kit to 
verify the expression of β-galactosidase reporter gene.  
3.4.3 BDNF Immunoassay 
 Strings were made from equal volumes of alginate containing similar 
Fb/BDNF cell concentrations/ml of alginate. The strings are suspended in Fb growth 
medium in 12 well culture plates. After 24 hours the medium is removed and an 
enzyme-linked immunosorbent assay (ELISA) is performed to verify the 
concentration of the BDNF that is released from the Fb/BDNF106. The assay consists 
of a microplate pre-coated with a monoclonal antibody specific for BDNF. 
Standards, samples and controls were pipetted into the wells and any BDNF present 
would then be bound by the immobilized antibody. An enzyme linked monoclonal 
antibody specific for BDNF was then added to the wells, which was followed by a 
wash to remove any unbound antibody-enzyme reagent. A substrate solution was 
then added to the wells and color develops in proportion to the amount of BDNF 
bound in the initial step. The intensity of the color produced was then read at 450nm 
using a spectrophotometer and compared to the standard to calculate the 
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concentration of BDNF present. 
3.5  Laminin Conjugated Alginate as a Growth Permissive Surface  
3.5.1  YIGSR-Alginate Conjugate Preparation 
 YIGSR a pentapeptide of laminin is obtained from American Peptide 
Company. The peptide is bound to the alginate covalently through an amide bond 
formation between the carboxyl groups of the alginate and the amine terminus of the 
peptide. This reaction is aided by a zero length crosslinker, 1-ethyl-3-(3-dimethyl 
aminopropyl) carbodiimide (EDC). Studies have shown that the amount of EDC 
present in the reaction has a dramatic effect on the efficiency of peptide 
incorporation. The EDC is also most reactive in an acidic pH of about 4.5 but a 
more neutral pH of 6.5 was necessary for peptide incorporation. A detailed 
description of the method is provided in the Appendix. Different peptide 
concentration and varying concentrations of the alginate carboxyl groups were 
activated to compare cell adhesion. Also entire laminin fragment was bound to the 
alginate using the same procedure and results compared. 
3.5.2  NB2a and SHSY5Y Cell Culture 
 NB2a and SHSY5Y are mouse and human neuroblastoma cell lines, 
respectively and were obtained as a gift from Prof. Shea (University of 
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Massachusetts, Lowell Campus). Both cell lines were cultured in 10cm culture 
plates with DMEM (without L-Glutamine) + 10%FBS + 2mM L-Glutamine + 2mM 
Antibiotics. The cells were passaged at approximately 70-80% confluency. 
3.5.3  Preparation of Modified Alginate Strings and Discs 
 Modified alginate strings were prepared using the same procedure as that used 
to make regular alginate strings. Once the strings are coated with PLO they are then 
coated with 1% (w/v) solution of the peptide modified alginate. NB2a and SHSY5Y 
cell adhesion and differentiation experiments were carried out using the modified 
alginate strings. Since the diameter of the chick embryo dorsal root ganglia (DRG) 
is greater than the width of the strings, modified alginate discs were prepared to 
verify DRG adhesion and neurite extension.  
Modified alginate discs were prepared using calcium sulfate (CaSO4) slurry91. 
A 1% (w/v) solution of modified or unmodified alginate was prepared in deionized 
water comprising 0.2% (w/v) of sodium metaphosphate which has a minimal effect 
on reaction efficiency. The addition of CaSO4 to alginate dissolved in DI water lead 
to formation of precipitates within the disc which could be avoided by the addition 
dissolving the alginate in sodium metaphosphate. The formation of precipitates may 
be due to the higher ionic strength of CaSO4 as compared to CaCl2 which could be 
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countered by the presence of sodium metaphosphate. The solution was sterilized by 
filtering through a 0.45µm syringe filter. The calcium sulfate slurry was prepared in 
deionized water at a concentration of 0.4g/ml and sterilized by autoclaving. The 
required volume of alginate was transferred into a 50 ml centrifuge tube to which 
the calcium sulfate slurry was added at a concentration of 20µl/ml of alginate. The 
solution was then shaken vigorously before being poured out into the wells of a 6 
well culture plate and allowed to set for an hour. This was carried out in a laminar 
flow hood to keep the discs sterile and they were then ready for cell adhesion studies. 
3.5.4  Cell Adhesion to Peptide Modified Alginate 
 NB2a and SHSY5Y cell adhesion to peptide modified alginate was studied 
and compared using varying concentrations of peptide, varying the peptide bound to 
the alginate and also by varying the concentration of carboxyl groups in alginate that 
were activated. Modified alginate strings made from equal volumes of alginate were 
placed in each well of a 12 well culture plate. NB2a and SHSY5Y cells were 
harvested from culture using 0.25% trypsin, centrifuged , counted and resuspended 
in serum free medium made up of DMEM + 10% serum replacement + 2mM L-
Glutamine. The strings were seeded with 500,000 cells per well and incubated at 
37°C at 5% CO2 for 24 hours. The strings were washed thoroughly with Hank’s 
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buffered salt solution to remove any unattached cells. The strings were transferred to 
wells of a new 12 well culture plate and treated with 0.25% trypsin 3ml for 5 
minutes and incubated at 37°C to detach the cells from the alginate strings and 
resuspended in growth medium. The cell were centrifuged, stained and counted 
using a hemocytometer. The statistical significance of cell adhesion to the alginate 
strings was calculated using Prism 3.0 statistics software package. 
This experiment was repeated where the concentration of the peptide added 
was varied and also a comparative cell adhesion study was performed using YIGSR 
and laminin at varying concentrations. Cell adhesion studies were also conducted by 
varying the concentration of carboxyl groups of alginate that were activated. 
Unmodified plain alginate strings were employed in all the above experiments to act 
as controls. The protocol for counting cells using a haemocytometer is provided in 
the appendix. 
3.5.5  Cell Differentiation on YIGSR Modified Alginate Strings 
 The neuroblastoma cell lines were also studied for their ability to extend 
neurites along the alginate strings to verify if these strings could act as guidance 
channels. Alginate strings were made from equal volumes of YIGSR modified 
alginate and placed in 12 well culture plates as explained in section 3.5.4. After 24 
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hours when the strings were washed with Hanks salt solution to remove any 
unattached cells, the strings were resuspended in prewarmed specific differentiation 
medium. For NB2a cells the differentiation medium consists of serum free medium 
+ 0.1% FBS + 10µM Dibutryl cyclic adenosine monophosphate (DbcAMP) and for 
the SHSY5Y cells the differentiation medium includes serum free medium + 0.1% 
FBS + 5µM Retinoic acid (RA). The differentiation medium was replaced everyday 
to replenish the DbcAMP and RA respectively. Cell differentiation and neurite 
extension were observed for a week using a microscope and pictures were taken 
periodically using a DP-11 digital camera (Olympus Optical Co. Ltd., Japan) 
mounted on the microscope. 
3.5.6  Chick Embryo Dorsal Root Ganglion Extraction 
Fertilized white Leghorn eggs were obtained from Charles River Laboratories 
Inc., Wilmington, MA. The eggs were placed in an incubator with an automatic 
turner at 39°C which is the ideal temperature recommended for embryo growth. 
Eggs were removed from the incubator between days 8 and 10 for dissection. Eggs 
were sprayed with alcohol before their shells were cracked open and embryos 
extracted. The embryos were place in sterile culture plates and dissected using 
dissecting forceps under a dissecting microscope. The thoracic cavity of the embryo 
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was split open following which the organs were removed piece meal to expose the 
spine. The DRGs were then collected from either side of the lumber vertebrae and 
placed in a culture plate with Hams F-12 medium. Aforementioned steps were 
carried out under aseptic conditions.  
3.5.7  DRG Adhesion and Growth on Laminin Modified Alginate 
Once the dissections were completed the DRGs were placed on laminin 
modified alginate discs. The DRGs were allowed to sit on the laminin modified 
discs in 6 well culture plates for 15 minutes to ensure adhesion before medium was 
added to it. The DRGs on 3 discs were exposed to 1ml fibroblast growth medium 
each; DRGs on 3 discs were exposed to 1ml fibroblast growth medium each that 
was removed from three wells of a 12 well culture plate containing modified 
alginate strings with 106 Fb/BDNF (~ 10ng of BDNF). DRGs on 3 other discs were 
exposed to 1ml of fibroblast growth medium supplemented with 10ng of human 
BDNF (Sigma) each. DRG adhesion and neurite extension on the laminin modified 
alginate discs was observed for 48 hours and images were captured at 24 and 48 
hours using an inverted Nikon microscope model TE2000 and phase contrast 
pictures were also captured using an Olympus camera mounted on an inverted light 
microscope. The length of the neurites was measured using Northern Eclipse 
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software. Thirty randomly chosen neurites were measured from each DRG and 
plotted on a graph and statistical analysis of one way ANOVA was performed using 
Graph Pad software. 
   3.6 Efficiency of PLO Coating on Immunoglobulin Exclusion 
The alginate strings were coated with poly-L-ornithine of molecular weight of 
15,000 – 30,000. This would help to prevent host immune cells from entering the 
graft and acting on the ensheathed Fb/BDNF. The efficiency of this PLO coating 
could be verified by exposing the modified alginate strings containing the Fb/BDNF 
to a cell specific antibody. The cells would then be removed from the strings and 
treated with a fluorescent secondary antibody. The cells would only take up the 
secondary antibody if the primary antibody had managed to get on the cells eluding 
the PLO coating. The antibody chosen for this experiment was the IgG antibody to 
the peroxisomal membrane protein 70 (PMP 70) (molecular weight 70kDa), which 
is a high-abundance integral-membrane component of peroxisomes108 and 109.  The 
molecular weight of the most common antibodies found in the body ranges from 65 
to 150kDa. Peroxisomes are single membrane-bound vesicles that are found in all 
animal cells except red blood corpuscles (RBC’s). The function of peroxisomes is 
enzymatic oxidation of fatty acids and catalyzes the breakdown of hydrogen 
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peroxide (H2O2) that is a byproduct of fatty acid degradation. Alexa Flour 488 
peroxisome labeling kit which is a fluorescent antibody labeling kit was obtained 
from Molecular Probes (Eugene, OR).  
The Fb/BDNF ensheathed in alginate strings with and without PLO coating, 
that were freshly made and those that were frozen and thawed, were exposed to the 
anti-PMP 70 antibody. The strings were incubated at 37°C for 2 hours. The cells 
were then isolated from the strings by dissolving them in sterile 10% (w/v) EDTA 
solution. The cells were plated on cover slips, fixed with methanol free 16% (w/v) 
formaldehyde solution and exposed to the Alexa Fluor 488 fluorescent secondary 
antibody and incubated for 30 minutes at 37°C. The secondary antibody would bind 
only to the cells that have the primary antibody on them. The cells were then 
viewed using an Eclipse TE 2000U inverted fluorescent microscope (Nikon, 
Melville, NY) and pictures were taken using a Cool Snap Photometrics camera 
(Roper Scientific, Tucson, AZ). This experimental setup would help to determine if 
the PLO coating is effective in keeping the IgG immunoglobulins from entering the 
alginate strings and affecting the Fb/ BDNF and help to verify if the strings could 
be grafted without immune suppressive therapy. 
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4. RESULTS AND DISCUSSION 
In this thesis we developed a graft made of alginate that would have 
applications in aiding spinal cord regeneration. We hypothesized that modifying the 
alginate with laminin would aid in neuronal cell adhesion and growth. We also 
hypothesized that ensheathing genetically engineered fibroblasts in the graft would 
not only provide growth factors for neurons but would also avoid immune 
suppression that would be required. 
 Grafts were designed and optimized in the form of alginate strings by varying 
the type of alginate; needle size and syringe pump speed. The graft was hen further 
optimized by modifying it with laminin which is a component of the basement 
membrane and would aid in neuronal cell adhesion. The ideal conditions were 
optimized by using varying laminin concentration and also varying the moles of 
carboxyl groups involved. Genetically engineered fibroblasts that produce BDNF 
were ensheathed in the alginate strings and these strings were then studied in vitro 
for their effects on neuronal cell adhesion and growth. Lastly the strings were also 
frozen and thawed at specific time intervals to verify if this graft could be stored and 
made readily available for grafting soon after injury. 
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4.1 Cell Adhesion to YIGSR Modified Alginate Strings 
Modified alginate strings were produced as described in Appendix 2 under 
sterile conditions. Modified alginate strings made from 1ml of alginate were placed 
in 6 wells of a 12 well culture plate. The remaining 6 wells contained strings made 
from 1 ml of plain alginate Another set of controls was prepared with 6 wells 
containing strings made from 1 ml of plain alginate and coated with PLO to 
examine the effect of the PLO coating had on cell adhesion. Two different 
neuroblastoma cell lines were used to estimate the cell adhesion to the modified 
alginate strings. The NB2a cells are the rat neuroblastoma cells while the SHSY5Y 
cells are human neuroblastoma cells. These cells are also model cell lines derived 
from neuroblastomas and would not exactly mimic the neurons in vivo. These cells 
were undifferentiated and required specific differentiating factors to extend neurites. 
The neuronal cells in the body would however be differentiated cells and results 
may not be similar to that of the undifferentiated cells in the presence of 
differentiating factors. The NB2a cells grow more confluently than the SHSY5Y 
cells. The cells were added at a concentration of 5*105 cells per well to 3 wells each 
of the modified alginate strings, plain alginate strings and plain alginate strings 
coated with PLO. One ml of plating medium (DMEM with 2mM L-glutamine + 
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10% serum replacement +2mM antibiotic solution) was added to each of the wells. 
The serum replacement lacks fibronectin that is found in fetal bovine serum and 
would not affect the cell adhesion. This would help to ensure that the cell adhesion 
was solely influenced by the peptide bound to the alginate and not by fibronectin 
present in serum. The culture plates were incubated at 37°C at 5% CO2 for 24 hours 
following which pictures were taken under the microscope and the strings were 
removed with sterile forceps and placed in wells of a fresh culture plate and washed 
with Hanks buffered salt solution thoroughly. The strings were then trypsinized and 
resuspended in growth medium and the medium was removed and centrifuged. The 
cells were then stained with 0.4% trypan blue and counted using a haemocytometer.  
Figure 4.1.1 shows the results of the cell adhesion to the different types of 
strings made from 1ml of alginate. The results show that the SHSY5Y cell adhesion 
to the modified alginate strings is about 26.4% of the initial concentration of cells 
added and the NB2a cell adhesion to the modified alginate strings is about 34.8% of 
the initial concentration of cells added. Since the strings are in serum free medium 
the cells would not have enough nutrients for significant replication. Both sets of 
controls show no significant cell adhesion to either cell type. The above cells show 
that the NB2a cells show significantly better adhesion (p<0.01) to the modified 
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alginate strings than the SHSY5Y cells. Figure 4.1.2a and b show NB2a and 
SHSY5Y cell adhesion to modified alginate strings. The NB2a cells are more 
confluent in culture and robust when compared to the SHSY5Y cells, which might 
be the reason for their better adhesion to the modified alginate strings. These are 
light micrographs take 24 hours after seeding at a magnification of 250X. This 
proves that strings made from alginate modified with YIGSR do promote neuronal 
cell adhesion. Plain alginate has no intrinsic cell adhesive properties and PLO by 
itself does not affect cell adhesion.  
4.1.1 Cell Adhesion with Increasing Peptide Concentration 
Previous experiments done by Dr. Dhoot in our lab showed that cell adhesion 
on modified alginate discs improved with increasing peptide concentration. NB2a 
cells were used in all subsequent experiments since they were confluent in culture 
and easier to handle. The initial concentration of peptide used to modify the alginate 
was 1mg/gm of alginate based on previous work. The concentration of peptide was 
varied, ranging from 1mg/gm of alginate to 4mg/gm of alginate. An experimental 
setup consisted of a 12 well culture plate containing 3 wells each of modified 
alginate strings made from 1 ml of alginate with varying YIGSR concentrations. 
NB2a cells were added to each of the wells at a concentration of 5*105 cells per well. 
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The strings were suspended in plating medium for 24 hours and the strings were 
then removed washed thoroughly and the cells counted as described earlier. The 
results are shown in figure 4.1.3.  
The results show that there was an increase in NB2a cell adhesion as the 
concentration of YIGSR increased. Statistical analysis using a one way analysis of 
variance showed that while there was a significant increase (p<0.01) in NB2a cell 
adhesion between 1 and 2 mgs of YIGSR there was no significant increase (p>0.5) 
in cell adhesion between 2 and 3 mg. These results show that the maximum cell 
adhesion was achieved with 2 mg of YIGSR/gm of alginate with 0.05 moles of the 
carboxylate groups activated. This shows that more YIGSR bound to the alginate 
provides more adhesion sites for the cells thereby improving the percentage of cell 
adhesion. These results relate to the maximum peptide loading achieved with 0.05 
moles of the carboxyl groups on the alginate activated in terms of adhered cells. 
This indicated that the number of cells adhering to the modified alginate in the form 
of strings had reached a maximum; with 2mg of YIGSR with 0.05 moles of the 
carboxylic acid groups were activated. This does not however tell us whether the 
maximum peptide that could be loaded with 0.05 moles of carboxylic acid groups 
activated would be 2 mg. The maximum peptide loading on alginate might however 
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have to be calculated using a high performance liquid chromatography. These results 
also did not prove if the optimum cell adhesion with modified alginate strings had 
been achieved.  
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34.8% 26.4% 
Figure 4.1.1: Neuronal Cell Adhesion to Different Types of Strings.  
The graph depicts the amount of NB2a and SHSY5Y cells that attached to modified alginate 
strings and the plain alginate strings (Controls S and N) and alginate strings coated with just 
PLO (PLO S & PLO N), after 24 hours. The Y-error bars represent the standard error and 
n=3. The average cell count of the SHSY5Y cells was 132,000(26.4%) and that of the NB2a 
cells was 174,070 (34.8%). The average cell count of the SHSY5Y and NB2a cells on the 
control samples were 5900 and 12,300 respectively. The average SHSY5Y and NB2a cell 
adhesion to the PLO coated strings were 3140 and 4860 respectively. The values are a 
percentage of the cells originally added to each well containing the alginate strings. The X 
axis represents the different string types and the Y axis represents the cell count. 
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b. 
a. 
Figure 4.1.2a and b: NB2a and SHSY5Y Cell Adhesion on Modified 
Alginate Strings 
The pictures are light micrographs taken at a magnification of 250X. 
Figure a. shows NB2a cells on modified alginate strings and b. shows 
SHSY5Y cells. The dotted lines represent the borders of the strings, the 
arrows show the cells and the size bar represents 100µm 
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Figure 4.1.3: NB2a Cell Adhesion with Increasing Peptide Concentration
This graph is a quantitative comparison of cell attachment of the NB2a and the cells to 
modified alginate strings with increasing YIGSR loading per gram of alginate at 24 
hours. The Y-error bars represent the standard error. The average cell counts of the 
NB2a cells to 1mg YIGSR/g of alginate was 166,667 (33.3%), to 2mg/g of alginate was 
237,500 (47.5%), to 3mg/g of alginate was 262,500 (52.5%) and to 4mg/g of alginate 
was 258,333(51.6%), n=3. The increase in cell adhesion between 1 and 2mg YIGSR/g 
of alginate is statistically significant ‘++’ (p<0.1). The X axis represents the YIGSR 
concentration/g of alginate and the Y axis represents the cell count. 
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4.1.2 Effect of Surface Peptide Density on Cell Adhesion 
 To further increase cell adhesion we increased the moles of carboxyl groups 
of alginate that were activated while varying the concentration of the peptide added. 
The concentrations of EDC and N-hydroxysulfosuccinimide used in the activation 
step were varied according to the specific number of moles per gram of carboxyl 
groups that were to be activated. Equal concentrations of the YIGSR pentapeptide 
were added to these samples. The moles of hydroxyl groups activated ranged from 
0.05 moles to 0.5 moles per gram of alginate. This experiment was then repeated for 
increasing concentrations of the peptide ranging from 1mg/gm of alginate to 3 
mg/gm of alginate. The experimental set up was similar to that described previously. 
NB2a cells were added at a concentration of 5*105 cells per well to modified strings 
made from equal volumes (1 ml) of alginate. Figures 4.1.3, 4.1.4 and 4.1.5 show the 
results of cell adhesion with increasing moles of carboxyl groups activated for 
different peptide concentrations. The results showed that there was an increase in 
NB2a cell adhesion with increasing peptide concentration and increasing moles of 
carboxyl groups being activated. Maximum cell adhesion was achieved with 3mg of 
YIGSR per gram of alginate with about 0.3 moles of the carboxyl groups of the 
alginate being activated. These results showed that more peptide could be 
conjugated to the alginate when more carboxyl groups were activated, in terms of  
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Figure 4.1.4: NB2a Cell Adhesion to Alginate Strings Modified with 1mg 
YIGSR/gm of Alginate with Varying Concentrations of Carboxyl Groups 
Activated 
This graph is a quantitative comparison of cell attachment of NB2a cells to alginate strings 
modified with 1mg YIGSR per gram of alginate with varying moles of carboxyl groups being 
activated. The Y-error bars represent the standard error. The average cell adhesion to strings 
with 0.05M of –COOH activated was 166,666.7 (33.3%), to 0.1M was 216,666.7 (42.5%), to 
0.2M was 208,333.3 (41.7%), to 0.3M was 220,833.3 (44.2%) to 0.4M was 200,000 (44%) and 
to 0.5M was 208,333.3 (44.2%). There was no statistically significant difference in cell 
adhesion to the different groups. The X-axis represents the varying moles of –COOH groups in 
alginate that were activated. 
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Figure 4.1.5: NB2a Cell Adhesion to Alginate Strings Modified with 2mg 
YIGSR/gm of Alginate with Varying Concentrations of Carboxyl Groups 
Activated 
This graph is a quantitative comparison of cell attachment of NB2a cells to alginate strings 
modified with 2mg YIGSR per gram of alginate with varying moles of carboxyl groups being 
activated. The Y-error bars represent the standard error. The average cell adhesion to strings with 
0.05M of –COOH activated was 237,500 (47.5%), to 0.1M was 225,000 (45%), to 0.2M was 
291,666.7 (58.3%), to 0.3 M was 287,500 (57.5%), to 0.4M was 304,166.7 (60.8%) and to 0.5M 
was 295,833.3 (59.1%). There was a statistically significant (p<0.01) increase in cell adhesion with 
the 0.2, 0.3, 0.4 and 0.5 moles of –COOH groups being activated compared to 0.1M group. The X-
axis represents the moles of –COOH groups activated and the Y-axis represents the cell count.  
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Figure 4.1.6: NB2a Cell Adhesion to Alginate Strings Modified with 3mg 
YIGSR/gm of Alginate with Varying Concentrations of Carboxyl Groups 
Activated 
This graph is a quantitative comparison of cell attachment of NB2a cells to alginate strings 
modified with 2mg YIGSR per gram of alginate with varying moles of carboxyl groups being 
activated. The Y-error bars represent the standard error. The average cell adhesion to strings with 
0.05M of –COOH activated was 233,333.3 (46.7%), to 0.1M was 237,500 (47.5%), to 0.2M was 
300,000 (60%), to 0.3M was 337,500 (67.5%), to 0.4M was 350,000 (70%) and to 0.5M was
325,000 (65%). There is a statistically significant (p<0.01) increase in cell adhesion to the groups 
where 0.3 and 0.4 moles of –COOH groups were activated and (p<0.05) in the 0.5M group as 
compared to the 0.05M group. The X-axis represents the number of moles of –COOH groups in 
alginate that were activated. The Y-axis represents the cell count. 
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cell adhesion. Varying the concentration of the EDC and sulfo-NHS added to the 
alginate helped to activate a higher number of carboxyl groups. Free carboxyl 
groups that were not bound to the calcium ions would be available for the YIGSR 
peptide to bind to. Since alginate has non inherent cell adhesion properties the 
percentage of cells adhering to the strings would depend on the concentration of 
peptide bound to the alginate. Higher concentration of peptide would lead to more 
cell adhesion sites in the available surface area of the graft. These results helped to 
confirm that the loading of YIGSR peptide to the alginate could be increased by 
increasing the moles of carboxyl groups that were activated, which was 
demonstrated by the increase in NB2a cell adhesion. Increasing the peptide loading 
above 3mg per gm of alginate or further increasing the moles of carboxyl groups 
activated did not significantly enhance cell adhesion. The reason for this could be 
that the maximum peptide that could be loaded to alginate had been reached. It 
could also be due to the fact that the maximum cell adhesion to the graft in the shape 
of strings had been achieved. Since cells have shown better adhesion and 
communication on flat surfaces, the cylindrical shape might have an influence on 
limiting their adhesion. Previous experiments done on cell adhesion on flat surfaces 
consisting of alginate discs modified with YIGSR have shown better cell adhesion110. 
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Discs made from alginate modified with 2mg of YIGSR/gm of alginate with 0.05 M 
of the carboxyl groups have shown 65% - 70% cell adhesion when seeded with 
NB2a cells. Therefore the cylindrical shape of the graft might indeed play a role in 
cell adhesion. These results only prove that the optimum cell adhesion to the 
modified alginate strings had been achieved with a peptide loading of 3mg/gm of 
alginate with 0.3 to 0.4 M of carboxyl groups being activated. Loading more peptide 
might also lead to the crowding of adhesion sites which present as a single adhesion 
site. Also loading of high concentrations of peptide would lead to down regulation 
of axon growth from the adherent neuronal cells.  
   4.2 Cell Differentiation on Modified Alginate Strings 
Since cell adhesion had been established by the above experiments the next 
step was to verify if these cells would extend neurites along the strings thereby 
showing that these strings could act as a bridge at the injury site. Since the cell lines 
that we employed were undifferentiated cells specific differentiation factors had to 
be added once cell adhesion was achieved. The specific differentiation factors for 
the NB2a and the SHSY5Y cells are Dibutryl cyclic adenosinemonophosphate and 
retinoic acid respectively. The experimental setup for neuronal cell differentiation 
was the same as was described in section 3.5.5. The cells were observed for neurite 
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extension for a week and pictures were taken. Figures 4.2.1a and b show neurite 
extension from NB2a and SHSY5Y cells respectively, after 2 days in differentiation 
medium. Figure 4.2.2 shows SHSY5Y differentiation on modified alginate strings 
after 7 days exposure to differentiation medium. These results show that these cell 
lines adhered to the modified alginate strings and also extended neurites. The 
SHSY5Y cell line showed neurite extension along the string indicating that these 
strings could act as a physical bridge at the injury site. The NB2a cells showed 
neurite extension but these were short and did not show extensions along the strings 
similar to the SHSY5Y cells. The modified alginate strings would be the best 
surface available for the neurons when grafted at the injury site. We can surmise that 
in vivo, once they lay down on the modified alginate strings the neurons would 
extend along the strings to communicate with other neurons. 
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b. 
a. 
Figures 4.2.1a and b: NB2a and SHSY5Y Cell Differentiation on 
Modified Alginate Strings at 48 hours 
Light micrographs showing NB2a and SHSY5Y cells on modified alginate 
strings at 250X respectively. Arrows show the neurites extending from the 
cells. Dotted white line indicates the border of the string which extends 
from the top of the picture towards the bottom right side. The size bars 
represent 100µm 
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Figure 4.2.2: SHSY5Y Cells on Modified Alginate String at Day 7 
A light micrograph taken at a magnification of 625 X showing neurite extensions 
from SHSY5Y cell bodies on a piece of modified alginate string. The orange 
circle marks the SHS5Y cell bodies, the blue arrow shows the neurites and the 
yellow arrow points to the border of the string, which extends from the top left of 
the picture to the bottom right side. The size bar represents 100µm. 
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4.3 In Vitro Evaluation of Genetically Engineered Fibroblasts Ensheathed in 
Modified Alginate Strings 
Rat abdominal skin fibroblasts that were genetically engineered to produce 
BDNF were ensheathed in the alginate strings by suspending them in the alginate 
solution from which the strings were made. This was done so that the graft when 
applied to the injury would also act as a source of neurotrophic factors at the site. 
The aim of ensheathing the fibroblasts in the modified alginate strings is to protect 
the cells from the host immune system while allowing the BDNF to diffuse into the 
host injury site. The survival and behavior of these ensheathed fibroblasts were then 
tested in vitro. Fibroblast cell survival and growth in modified alginate strings, 
transgene expression and quantification of BDNF release were investigated. 
BDNF producing fibroblasts were obtained from Dr. Fisher’s laboratory at 
Drexel University College of Medicine, where fibroblasts obtained from adult 
Sprague Dawley rats had been modified using a recombinant retroviral vector (as 
seen in figure 4.3.1) to produce BDNF. The retroviral construct comprises of the 
human BDNF transgene linked with a reporter gene which would facilitate the 
monitoring of the BDNF expression. The reporter gene used in this case was LacZ 
which codes for the bacterial enzyme β-galactosidase. The long terminal repeats 
(LTR’s) and the internal ribosome entry sites (IRES) in the retroviral vector are 
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responsible for the expression of the BDNF transgene and the reporter gene via 
transcription of a polycistronic messenger ribonucleic acid (mRNA). The procedure 
for making the recombinant retroviral vector and transfection of the fibroblasts with 
the vector have been described in detail by Liu at al100. They also calculated that the 
rate of BDNF released from these fibroblasts was about 12.8 ng per million cells per 
24 hours using the slot blot technique. 
4.3.1 Fb/BDNF Growth in Modified Alginate Strings 
Fibroblasts were ensheathed in modified alginate strings as described in 
section 3.3.2. The fibroblasts were suspended in sterile saline at pH 7.4 and added to 
a 1.5% (w/v) alginate solution to make a 1% (w/v) solution before the strings are 
made. The strings are then made and coated as descried in sections 3.2.1 and 3.2.2. 
The cells were loaded at a concentration of 3*106 cells per ml of alginate and strings 
were placed in the wells of a 12 well culture plate in growth medium. Strings made 
from 1 ml of alginate were placed in each well and strings from 3 wells were 
removed at day 7, 14 and 21 and dissolved in EDTA to verify cell survival. The cells 
were stained with 0.4% methylene blue vital stain. Figures 4.3.2a and b show 
modified alginate strings with the Fb/BDNF ensheathed in them. 
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 The cells were found singly and dispersed evenly throughout the strings. 
Experiments done previously by other researchers, where cells were 
encapsulated in microcapsules, the cells were found to aggregate in the centre of 
the capsule forming what were termed “fibrospheres”76. No such phenomenon 
was observed with the modified alginate strings. The results of Fb/BDNF cell 
survival are shown in figure 4.3.3. The results show that about 93 – 95% of the 
cells survive upto 3 weeks in growth medium. There is no significant (p>0.5) 
difference in cell survival between the different time intervals. The lack of 
significant increase in cell count could be due to death of cells that were in the 
middle of the strings since they would not receive nutrients as opposed to cells 
that were closer to the surface that would communicate better with the external 
environment. These cells on the surface might reproduce while the cells closer to 
the center of the strings probably died due to lack of nutrients. There may have 
been cell loss while strings were being dissolved in EDTA. Unlike the studies 
with alginate microcapsules by Dr. Dhoot where encapsulation of higher 
concentration of cells lead to loss of capsule integrity after 7 days in culture, 
there were no visible changes in the string integrity and the cells did not 
aggregate suggesting that the concentration of cells per ml of alginate could be 
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increased. Once cell survival was verified the next step was to verify reporter 
gene expression and quantify BDNF secretion. 
4.3.2 X-Gal Staining of Fb/BDNF in Strings 
The alginate strings would be effective in enhancing neuronal regeneration in 
vivo if the Fb/BDNF continued to secrete BDNF for about 3-4 weeks at a 
concentration of about 20-30ng per 24 hours. Previous experiments, where 
genetically modified cells were encapsulated in alginate, show that the cells 
continued to express their active components like growth factors, proteins and other 
peptides72, 73, 100, 101. To verify BDNF expression from the cells ensheathed in the 
strings they were stained for the β-Galactosidase marker as described in section 
3.4.1. Figure 4.2.4a shows staining of the Fb/BDNF for the reporter gene 2 weeks 
after ensheathing in strings. Figure 4.3.4b shows cells, which were released from the 
strings by dissolving them in EDTA, staining for the β-Galactosidase marker after 3 
days in culture. The reporter gene staining of cells released from the strings was 
found to be similar to free Fb/BDNF in culture. These results showed that the 
Fb/BDNF continued to express the BDNF transgene when cultured in vitro, 2 weeks 
after being ensheathed in modified alginate strings. Fb/BDNF that were released 
from these strings also showed transgene expression upon staining which was 
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comparable to free Fb/BDNF in culture. This experiment showed that the Fb/BDNF 
cells were still receiving nutrients from the growth medium to keep them alive and 
that their transgene expression had not been inhibited by the process of ensheathing 
them in the strings. Previous in vivo work done by Dr. Dhoot, with encapsulated 
cells in rat spinal injury models, showed that capsules that were harvested 2-4 weeks 
after transplant showed down regulation of reporter gene activity as compared to 
that in culture prior to grafting. The harvested cells showed increase in transgene 
expression when placed in culture for a week suggesting that the in vivo down 
regulation might be the result of soluble factors since the Fb/BDNF had no direct 
contact with the spinal cord. Also following grafting cytokines might cross the 
semipermeable membrane of the graft, which would allow free diffusion of 
substances with a molecular weight lower that 70kDa. The study also found that the 
Fb/BDNF cells survived in the alginate capsules for a period of 1 month and 
continued to express the transgene, though down regulated and there was axon 
growth observed in the cavity region. The above experiment used a concentration of 
3*106 Fb/BDNF cells/ml of alginate and about 20-40 micro capsules were required 
to fill the lesion cavity. Previous studies by Liu et al, where Fb/BDNF were directly 
transplanted into the lesion, used a cell concentration of 5*104 cells106 and 107. So 
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b. 
a. 
Figure 4.3.2a and b: Fb/BDNF in Modified Alginate String 
Light micrographs showing Fb/BDNF in a piece of modified 
alginate string at 625X and 1000x respectively. The white dotted 
line represents the border of the string, the white arrows show the 
Fb/BDNF and the black line represents a scale of 100 µm 
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Figure 4.3.3: Fb/BDNF Cell Survival in Modified Alginate Strings, Suspended 
in Growth Medium, Over Time 
This graph is a quantitative comparison of fibroblast survival, in equal volumes of alginate strings 
placed in growth media, at specific time points and n=3. The Y-error bars represent the standard 
error. The average cell count after 7 days was 2,858,333 (95.3%) , after 14 days was 2,825,000 
(94.2%) and after 21 days was 2,802,000 (93.4%) of the initial cell concentration. 
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b. 
a. 
Figure 4.3.4a and b: X-Gal Staining of Fb/BDNF in Strings and 
when Released From Strings 
The cells show a bluish green staining for the reporter gene. Figure a. 
is a light micrograph at 250X and b. Cells released by EDTA 
treatment viewed at 1000X. The arrows show the Fb/BDNF cells 
inside the strings. The size bars represent 100µm 
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depending on the size of the graft required the concentration of the cells has to be 
varied so as to produce approximately 10-20ng of BDNF/24 hours for a period of 
upto 1 month in vivo obtain desirable results. 
4.3.3 In vitro Quantification of BDNF Secretion Using ELISA 
The next step was to verify the concentration of BDNF secreted from the 
Fb/BDNF cells that were ensheathed in the modified alginate strings. This was done 
to see if the alginate string or the PLO coating or the peptide modified alginate 
played a role in influencing BDNF release. Experiments were set up with Fb/BDNF 
(at a concentration of 1*106 cells in 1ml of alginate) in plain alginate strings, strings 
coated with PLO, strings coated with PLO and YIGSR modified alginate suspended 
in growth medium. Fb/BDNF (1*106 cells per well) cells in culture were used as 
controls. The growth medium was removed from the samples after 24 hours and 
ELISA was performed, as described in section 3.4.3, to estimate the concentration of 
BDNF released. The results in table 4.3.5 show the concentration of BDNF released 
from the different experimental samples. The results show that the Fb/BDNF 
ensheathed in alginate strings released about 8ng of BDNF per 24 hours while a 
similar number of free Fb/BDNF in culture released about 10ng per 24 hours. 
Growth medium, alginate strings, PLO and YIGSR peptide showed 0ng confirming  
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Table 4.3.1: BDNF Release from Fb/BDNF Cells Quantified by ELISA 
 
SAMPLES BDNF CONCENTRATION 
(ng/24hours/million cells) 
Fb/BDNF in plain alginate strings 8.04 
Fb/BDNF in plain alginate strings + PLO 7.33 
Fb/BDNF in plain alginate strings + PLO 
+ YIGSR modified alginate 
7.45 
Free Fb/BDNF in culture 9.97 
Controls (Fb growth medium, plain 
alginate strings, strings + PLO, strings + 
PLO + YIGSR modified alginate) 
0.0 
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 that these factors did not influence the ELISA. Though there was a statistically 
significant difference (p<0.001) in BDNF secretion between the ensheathed and free 
Fb/BDNF there was no significant difference (p>0.05) in BDNF secretion from the 
cells in the strings with different coatings. The difference in BDNF concentration 
between the cells in the strings as opposed to cells in culture may be due to 
entrapment of BDNF in the alginate strings leading to a delay in its release. The 
release of the BDNF from the strings would be dependent on a number of factors 
such as the molecular weight of the alginate, the concentration of the calcium ions 
and the concentration of the peptide bound to the alginate which would all help to 
determine the pore size. Meanwhile the cells in culture would be unencumbered by 
any of these factors in their BDNF release. Previous experiments where Fb/ BDNF 
were directly transplanted in the lesion site, used cell concentrations ranging from 
5*105 cells to 3*106 cells112 and 113. These experiments showed that the modified cells 
had maximum transgene expression in the first week of grafting and then the 
expression was subsequently down regulated, but when the cells were removed from 
the animal and placed in culture, they upregulated gene expression and continued to 
express the transgene for a period of at least 2 months when the animals were 
sacrificed. The experiments helped to prove that the cells were secreting sufficient 
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neurotrophic factors to aid in preventing neuronal atrophy and also influence 
neuronal regeneration. Varying the concentration of the cells added to the graft in 
the above mentioned concentrations seemed to produce similar results with regards 
to neuronal survival and regeneration. So depending on the size of the lesion which 
would determine the size of our graft, we could then vary the concentration of the 
Fb/BDNF cells/ml of alginate accordingly to ensure sufficient BDNF (minimum ~ 
5ng/24 hours) release once grafted.  
4.4 In Vitro evaluation of Frozen Modified Alginate Strings with Fb/BDNF 
One of our aims was to evaluate storage of the graft so it would be readily 
available for transplant following injury. So we studied freezing as a method of 
storing the graft since it is a well established method of cell storage. Since there was 
no prior work on freezing grafts made of alginate we employed cell freezing 
protocol to study the effects of freezing the Fb/BDNF in modified alginate strings. 
Modified alginate strings made from equal volumes of alginate (1ml) with equal 
concentrations of Fb/BDNF (1*106 cells/ml) were placed in cryovials suspended in 
freezing media as described in section 3.4.2. In vitro evaluation was done to verify if 
the strings reconstituted on thawing. Other in vitro evaluation included studying the 
survival and transgene expression of Fb/BDNF from frozen modified alginate 
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strings.  
4.4.1 Fb/BDNF Survival in Frozen Modified Alginate Strings 
Modified alginate strings made from 1ml of alginate with 1*106 Fb/BDNF 
were suspended in freezing medium and placed in cryovials which were in turn 
placed in a time delayed freezing container at -85°C for 24 hours before being 
transferred to liquid nitrogen. The strings were removed at specific time intervals 
and thawed at 37°C and dissolved in a 10% (w/v) EDTA solution. The cells were 
then resuspended in growth medium, centrifuged and stained with methylene blue to 
identify and count the viable cells. Figure 4.3.1 shows the results of cell survival 
over a year. The results show that nearly 85% of the cells ensheathed initially 
survived the long term freezing and thawing procedures. There was also no 
significant difference (p>0.05) in cell survival between the different time points. 
Since the protocol did no affect cell survival over prolonged storage under freezing 
the next step was to verify if the thawed Fb/BDNF still expressed the transgene. 
 
4.4.2 X-Gal Staining of Fb/BDNF from Thawed Modified Alginate Strings 
Fb/BDNF cells that were removed from frozen strings by treating with EDTA 
were stained for the reporter gene using the X-Gal staining kit. Cells that were 
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removed from the frozen strings were resuspended in growth medium in a culture 
plate for 24 hours. They were then stained using the X-gal staining kit to verify 
transgene expression. Figure 4.3.2 shows the bluish green staining of the cells for 
the reporter gene. The result confirms that the freezing medium helped in protecting 
the cells and the cells continued to express the transgene upon thawing when placed 
in culture.  
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Figure 4.4.1: Fb/BDNF Cell Survival in Frozen Modified Alginate Strings 
Results show that about 85% of the Fb/BDNF cells survive long term freezing. 
There is no significant difference (p>0.05) in cell survival between the various 
time points. The error bars represent the error over the mean. 
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Figure 4.4.2: X-Gal Staining of Fb/BDNF Cells Released From Frozen 
Alginate Strings 
The cells released from frozen alginate strings using EDTA that were thawed, 
showed bluish green staining for the reporter gene confirming that the cells 
were still actively expressing the BDNF transgene. The light micrograph was 
taken at a magnification of 250X and the size bar represents 100X. 
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4.5 Chick Embryo DRGs on Laminin Modified Alginate 
To better mimic the effects of the graft in vivo we decided to use chick embryo 
dorsal root ganglia (DRGs). The rat and human neuroblastoma cell lines that were 
employed in the previous experiments were model cell lines. Thus these were 
undifferentiated cells and required specific differentiating factors for neurite 
extension. The DRGs are however differentiated cells and in the presence of 
medium with growth factors would start extending neurites in vitro that could be 
observed for a period of 48 hours. The DRGs require a laminin coated surface to 
adhere to before they could extend neurites113. The YIGSR pentapeptide sequence 
alone would not be sufficient for DRG adhesion since they require the entire laminin 
fragment. The initial idea was to coat alginate strings with laminin, but previous 
experiments performed by Dr. Dhoot with calcium alginate microcapsules proved 
that this method would be futile. When Ca-alginate microcapsules were coated with 
laminin the capsules started to fall apart even at concentrations as low as 1µg 
laminin per ml of alginate. This was due to the fact that laminin sequestered calcium 
from the calcium alginate complex leading to the disintegration of the hydrogel. The 
same was not observed in alginate hydrogels made with either barium or aluminum. 
This confirmed the results of other research that laminin formed large complexes 
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when it interacted with calcium ions102. So the next step was to covalently bind the 
laminin molecule to alginate utilizing carbodiimide chemistry as was the case with 
the pentapeptide YIGSR. 
4.5.1 Cell Adhesion on Laminin Modified Alginate Discs and Strings 
Alginate strings that were employed in prior experiments were found to be too 
small in width to allow for DRG adhesion since the DRGs were bigger than the 
NB2a and SHSY5Y cells that were employed. The alginate discs would provide a 
broader surface for the DRGs to adhere and extend neurites and help to verify the 
effectiveness of laminin modified alginate surface in vitro. Alginate discs were 
prepared using a CaSO4 slurry90 and then coated with PLO as with the strings. The 
discs were subsequently coated with alginate modified with laminin and washed 
repeatedly before they were used in cell adhesion experiments. DRGs removed from 
10 - 12 day old chick embryos were placed on laminin modified alginate discs in 6 
well culture plates and specific growth medium was added after 15 minutes. The 
discs in 3 wells were exposed to 1ml each of Fb growth medium removed from 
culture plate containing modified alginate strings, made from 1ml of alginate, with 
106 Fb/BDNF (~10ng of BDNF/ 24 hours) cells ensheathed in them. The discs in the 
other 3 wells were exposed to 1ml of DRG growth medium which consists of 
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fibroblast growth medium supplemented with 10ng of human BDNF. A similar 6 
well culture plate was also prepared with plain alginate discs in 3 wells that acted as 
controls, modified alginate discs with DRGs exposed to fibroblast growth medium 
without any BDNF supplement acted as controls in the other 3 wells. The culture 
plates were incubated at 37°C and pictures were taken under a microscope after 24 
hours. DRG adhesion and neurite extension was then verified and compared.  
The chick embryo DRGs adhere to the laminin modified alginate discs as seen 
in figures 4.5. The BDNF released into the medium, from the fibroblasts ensheathed 
in the modified alginate strings, induces the DRGs to produce neurites as seen in 
Figures 4.5.1a and 4.5.2a. DRGs on laminin modified alginate discs that were 
exposed to fibroblast growth media containing BDNF showed extensive neurite 
extension after 24 hours. DRGs on the control plate showed no neurite extension. 
Pictures were taken at 24 and 48 hours using an Olympus DP11 digital camera 
mounted on an inverted light microscope as well as a Nikon TE 2000 inverted light 
microscope as seen in Figure 4.5.3. The lengths of 30 random neurites on each DRG 
were measured, as shown in Figure 4.5.4, and a statistical analysis was performed. 
The average length of the neurites from DRGs exposed to fibroblast growth medium 
removed from culture plate with modified alginate strings with 1*106 Fb/BDNF was 
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about 0.49mm after 24 hours and 0.88mm after 48 hours. The average length of 
neurites from DRGs exposed to fibroblast growth medium supplemented with 10ng 
of human BDNF was about 0.55mm after 24 hours and 0.92mm after 48 hours. 
DRG studies done by other scientists also show that the DRGs exposed to growth 
factors such as BDNF and NGF show neurite outgrowth at a maximum rate of 1 mm 
per 24 hours114. A statistical one way ANOVA test performed comparing the neurite 
extension from the two experimental sets shows that there is no statistically 
significant difference (p>0.5) in the average length of neurites between the DRGs 
exposed to growth medium removed from strings containing Fb/BDNF and DRGs 
exposed to BDNF supplemented growth medium at 48 hours. However at 24 hours 
the average length of the neurites from DRGs exposed to BDNF supplemented 
growth medium was significantly (p<0.5) longer than the average length of the 
neurites of the DRGs exposed to growth medium removed from culture plate 
containing modified alginate strings with Fb/BDNF. This helped to prove that the 
BDNF was being actively secreted by the ensheathed fibroblasts and most of the 
BDNF being released was being expressed outside the strings. DRGs placed on 
plain alginate discs did not adhere to the discs showing that alginate has no intrinsic 
cell adhesive properties. 
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The above experiments have helped to better mimic an in vivo environment 
and helped us to better understand how these grafts might perform in animal models. 
The next step would be to find a way to effectively bundle the strings with sterile 
sutures so they could be readily grafted into spinal injury models in animals. 
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b. 
a. 
Figures 4.5.1a & b: DRG on Laminin Modified Alginate Disc 
 discs taken at 
24 hours at a magnification of 100X using an Olympus DP11 digital camera. a. Shows 
neurite extension from DRG exposed to fibroblast growth medium removed from culture 
plate containing modified alginate strings with 10 Fb/BDNF ensheathed in them. b. Shows 
neurite extension from DRG exposed to fibroblast growth medium supplemented with 10ng 
human BDNF. Black arrows show the neurites and the black line at the bottom represents a 
scale of 100µm 
Figures a and b are light micrographs of DRGs on laminin modified alginate
6
Figures 4.5.2a & b: DRG on Laminin Modified Alginate Disc 
Figures a and b are phase contrast micrographs of DRG on laminin modified alginate discs 
taken at magnification of 100X at 48 hours. a. Shows neurite extension from DRG exposed 
to fibroblast growth medium removed from culture plate containing modified alginate 
strings with 106 Fb/BDNF ensheathed in them. b. Shows neurite extension from DRG 
exposed to fibroblast growth medium supplemented with 10ng human BDNF. White arrows 
show the neurites and the white line at the bottom represents a scale of 100µm 
 
b. 
a. 
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Figure 4.5.3: DRG on Laminin Modified Alginate Disc at 48 Hours 
Shows a light micrograph of DRG on a laminin modified alginate disc taken at a 
magnification of 40X at 48 hours using a Nikon TE 2000 digital camera. Images 
taken under this microscope were used to measure neurite lengths. The arrows show 
the neurites and the white line at the bottom right represents a scale of 100µm 
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Figure 4.5.4: Average Length of Neurites Extending from 
DRGs Exposed to Different Media 
This graph shows the average length of 30 randomly selected neurites from 
DRGs exposed to different media. Fb/BDNF stands for fibroblast growth 
media removed from culture plate containing laminin modified alginate strings 
with 106 Fb/BDNF cells ensheathed. BDNF stands for fibroblast growth media 
supplemented with 10ng of human BDNF. At 24 hours DRGs exposed to 
BDNF media showed significantly (p<0.5) longer neurites than those exposed 
to Fb/BDNF. At 48 hours there was no statistically significant difference in 
average neurite lengths between both groups. Y error bars represent standard 
error, n=30  
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4.5.2 Effectiveness of PLO Filter on Exposure to Anti-PMP Antibody 
The function of the PLO coating is to prevent the high molecular weight 
immunoglobulins from entering the graft while allowing the Fb/BDNF to secrete the 
BDNF. While prior experiments with ELISA have proved that the  
BDNF is being released from the graft, exposing the graft to anti-PMP 70 
antibody would help to prove that the PLO filter is effective in guarding against 
immunoglobulins. The anti-PMP 70 antibody was chosen since it had a molecular 
weight of 70kDa which was the cut off for the semipermeable PLO filter and also it 
was a fluorescent antibody that would tag the cells making them clearly visible. 
Alginate strings, with 106 Fb/BDNF made from 1ml of alginate and coated with 
PLO and laminin modified alginate were placed in a 3 wells of a 12 well culture 
plate. A similar set of strings that had been frozen for 90 days were thawed in a 
37°C water bath were placed in 3 wells. Plain alginate strings, with 106 Fb/BDNF 
made from 1ml of alginate without any coating were placed in 3 wells and a similar 
set of frozen strings were thawed and placed in the remaining 3 wells. The strings 
were then incubated for 2 hours at 37°C with 1µl of anti-PMP 70 antibody in 1 ml of 
buffer. The cells were then removed from the strings using 10% (w/v) sterile EDTA 
and fixed on cover slips using methanol free 16% (w/v) formaldehyde for 15 
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minutes. The cells were then exposed to Alexa Fluor 488 secondary antibody for 30 
minutes under incubation. The cover slips were then observed under a Eclipse TE 
2000U inverted fluorescent microscope (Nikon, Melville, NY) and pictures were 
captured using Cool Snap camera (Roper Scientific, Tucson, AZ). 
 Fb/BDNF in plain uncoated alginate strings, both freshly made and those that 
were frozen and then thawed took up the anti-peroxisomal membrane protein that 
they were exposed to as shown in Figures 4.6.1a and 4.6.2a. This is indicated by the 
fluorescence exhibited by the cells that have taken up the fluorescent secondary 
antibody. The Fb/BDNF in strings that were coated with PLO, both freshly made 
and those that were frozen and then thawed showed no fluorescence as seen in 
Figures 4.6.1b and 4.6.2b. The lack of fluorescence is due to the absence of the 
Alexa Fluor 488 secondary antibody uptake by the cells plated on the cover slips. 
This proved that the primary anti-PMP 70 antibody failed to penetrate the string 
showing that the PLO coating proved efficient. Similar effects were observed in 
strings that had been frozen for a period of 90 days and subsequently thawed in a 
37°C water bath. This showed that the PLO coating on the strings was not 
compromised by the freezing and thawing procedures. 
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b. 
a. 
Figure 4.6.1a and b: Comparison of Antibody Uptake Between 
Cells Taken from Plain Alginate Strings and Strings Coated with 
PLO 
Figure a. shows cells from plain alginate string that was exposed to 
anti-PMP antibody and fluorescent secondary antibody taken at a 
magnification of 250X. Figure b. shows cells from PLO coated 
alginate strings that were exposed to the antibodies taken at 250X. 
The white arrows show the cells. The white bar represents a scale of 
100µm. 
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b. 
a. 
Figure 4.6.2a & b: Comparison of Antibody Uptake Between 
Cells Taken from Frozen Alginate Strings and Frozen Strings 
Coated with PLO 
Figure a. shows cells from frozen and thawed plain alginate string 
that was exposed to anti-PMP antibody and fluorescent secondary 
antibody taken at a magnification of 250X. Figure b. shows cells 
from PLO coated frozen and thawed alginate strings that were 
exposed to the antibodies taken at 250X. The white arrows show the 
cells. The white bar represents a scale of 100µm. 
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                       5. CONCLUSIONS 
This thesis evaluated the design and optimization of a novel graft in the form 
of alginate strings for use in treatment of spinal cord injury. The graft was designed 
to have a multifaceted action in aiding neuronal regeneration. Previous work and 
research in this field suggests the requirement for such treatment methods.  
The graft for spinal injury treatment was designed in the form of alginate 
strings so that it could act as a bridge for neurons to grow across. Studies showed 
that the 22 gauge needle and a flow rate of 13.5ml per minute were optimum for 
producing alginate strings. The graft in the form of strings could act as a physical 
bridge at the site of injury, but alginate in itself has no inherent cell adhesive 
property. To enhance neuronal adhesion and regeneration alginate was modified 
with specific basement membrane peptide. YIGSR a pentapeptide of laminin was 
conjugated to alginate using carbodimide chemistry. Neuronal cells in the form of 
rat (NB2a) and human (SHSY5Y) neuroblastoma cells were used to verify cell 
adhesion. Early results showed that about 30% of the cells added to the graft 
adhered to it when alginate was modified with 1mg of YIGSR/ gm of alginate. Also 
NB2a cells showed better adhesion to the graft than SHSY5Y cells. Further studies 
to enhance cell adhesion showed that increasing the concentration of the peptide 
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conjugated to alginate helped to improve cell adhesion to about 45%. Maximum cell 
adhesion was attained with 2mg of YIGSR when 0.05 moles of the carboxyl groups 
of alginate were activated. These results led us to believe that more peptide could be 
conjugated to the alginate if higher concentrations of carboxyl groups were activated. 
Cell adhesion results confirmed that more peptide could be loaded if the 
concentration of carboxyl groups activated was increased. Maximum cell adhesion 
of about 70% was achieved with 3mg YIGSR per gm of alginate with about 0.4 
moles of the carboxyl groups activated. The increase in the moles of carboxyl 
groups activated lead to an increase in the concentration of peptide that could be 
bound to alginate. The higher concentration of peptide helped to provide more 
adhesion sites thereby leading to an increase in the number of cells adhering to the 
modified alginate strings. The maximum percentage of cell adhesion could have 
been influenced by a number of factors like, maximum peptide that could be bound 
to alginate had been achieved, adhesion site crowding and high peptide 
concentration affecting cell adhesion. 
The neuroblastoma cell lines that were employed in the adhesion studies were 
model cell lines and hence were undifferentiated. When medium consisting of 
specific differentiation factors was added to strings with the cells adhered to them, 
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the cells started to produce neurites. The most promising results were observed with 
the SHSY5Y cells at day 7, where many string samples showed cell body 
aggregation and neurite extension along the string. This further confirmed the fact 
that these modified alginate strings could act as a bridge along which the neurons 
could attach and produce neurites thereby helping the neurons to communicate 
across the gap at the injury site. The NB2a cells produced neurites that were short 
and did not extend along the string as the SHSY5Y cells. These cells were 
undifferentiated cells and required specific factors in vitro to produce neurites. Axon 
sprouting and growth on the graft may vary in vivo since the cells are differentiated 
and require no special factors. 
Rat abdominal skin fibroblasts that were genetically engineered to express 
brain derived nerve growth factor were then ensheathed in these modified alginate 
strings. Experiments were performed to verify cell survival and transgene 
expression which showed that the fibroblasts in the strings survived in culture 
showing that the growth medium permeated into the strings. Unlike experiments 
were cells were encapsulated in alginate where the cells clumped together, there was 
no such phenomenon observed with the strings. The cell survival studies also 
showed no increase in cell count which may be due to the fact that the cells in the 
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center of the string could no communicate with the external environment thereby 
leading to their death due to lack of nutrients. The cells that were closer to the 
surface remained viable and reproduced maintaining a significant cell count. 
Staining for the reporter gene showed that the cells were still expressing the 
transgene while ensheathed in the alginate strings. These results were comparable to 
prior experiments done by Dr. Dhoot that showed that Fb/BDNF in alginate 
microcapsules continued to express the transgene in vitro. When the modified 
alginate strings with the Fb/BDNF are transplanted in vivo there might be a down 
regulation of transgene expression as experienced in studies with encapsulated 
Fb/BDNF. This would be due to exposure of the cells to cytokines that may pass 
through the semipermeable PLO coating and also due to the lack of exposure of the 
Fb/BDNF to the host tissue. 
An enzyme linked immunosorbent assay was performed to quantify the BDNF 
released from the Fb/BDNF cells that were ensheathed in the strings. It was found 
that 106 cells released approximately 10ng of BDNF per 24 hours and the same 
concentration of cells in modified alginate strings released about 8ngs of BDNF. The 
BDNF release from strings that were coated with PLO and alginate modified with 
YIGSR showed similar release as the release from Fb/BDNF in plain alginate 
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strings. This showed that neither the YIGSR nor the PLO coating had any inhibiting 
effect on BDNF release from the graft. Fb/BDNF that were frozen in modified 
alginate strings also showed comparable BDNF release when thawed which 
confirmed the fact that freezing and thawing did not affect BDNF release. The 
results while showing that there was no drastic fall in BDNF secretion it also would 
aid in deciding the concentration of cell loading depending on the volume of 
alginate that would be required to make the graft. 
The strings were frozen to make them readily available for grafting following 
injury. The modified alginate strings containing the Fb/BDNF were frozen using cell 
freezing protocols and cell survival, transgene expression and neuronal cell adhesion 
were verified. Experiments showed that approximately 85% of the Fb/BDNF cells 
survived freezing and continued to express the transgene. The freezing protocol used 
was the one used for cell storage and previous experiments on cryo preservation 
show cell survival of approximately 82-87%. This shows that this protocol could be 
used to store the graft. The strings also reconstitute on thawing thus making this 
process useful for storing the grafts for use when required. Neuronal cell adhesion 
was also found to be comparable to unfrozen strings showing that the YIGSR 
peptide was not affected by the freezing and thawing and continued to provide 
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adhesion sites for cell attachment. 
The strings were then modified with the entire laminin fragment to support 
chick embryo dorsal root ganglion adhesion. These experiments were done to better 
mimic an in vivo situation since the neuroblastoma cells we employed earlier were 
undifferentiated cells. Laminin modified alginate discs and strings bundles were 
made for DRG adhesion experiments since they are bigger in diameter than a single 
strand of string. Experiments showed that DRGs adhered to modified alginate discs 
and also produced neurites when exposed to medium removed from strings with 
Fb/BDNF. The average length of neurites extending from DRGs exposed to medium 
supplemented with human BDNF was comparable to those that were exposed to 
medium removed from culture plated with modified alginate strings containing 
Fb/BDNF. Though there was statistically significant (p<0.5) difference in length 
between the two groups at 24 hours there was no significant (p>0.5) difference at 48 
hours. This further helped to prove that the Fb/BDNF were surviving in the 
modified alginate strings and also actively expressing BDNF. The expressed BDNF 
also entered the surrounding medium thereby having a growth enhancing effect on 
the chick embryo DRGs. Previous studies have shown that 106 Fb/BDNF express 
about 10ng of BDNF per 24 hours and the above experiments have shown that the 
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average neurite length of the DRGs treated with human BDNF (10ng/ml) 
supplemented medium is comparable to those that are exposed to medium removed 
from culture plate with laminin modified alginate strings with Fb/BDNF expressing 
approximately the same concentration of BDNF. The difference in average neurite 
length between the two groups at 24 hours may be due to the fact that there may be 
an initial delay in the expression of the BDNF across the modified alginate strings 
into the surrounding medium. By 48 hours there is no significant difference in 
average neurite length thereby indicating that most of the BDNF expressed by the 
modified cells was released from the strings. The control experimental set up with 
unmodified alginate discs showed no DRG adhesion proving that alginate did not 
possess any intrinsic cell adhesive properties. The DRGs placed on laminin 
modified alginate discs, but exposed to fibroblast growth medium with no BDNF, 
showed adhesion but no neurite extension and this helped to prove that the medium 
had no effect on neurite extension per se. 
In this thesis, it has been shown that alginate strings modified with specific 
peptide promote neuronal cell adhesion and growth. Cell adhesion could be 
enhanced by increasing the concentration of peptide bound to the alginate by in turn 
increasing the moles of carboxyl groups activated. The model cell lines that were 
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employed in early experiments showed that neuronal cells could adhere to the graft 
and produce neurites that would extend along the length of the graft. This also 
helped to show that this graft could act as a physical bridge in vivo for axons to 
grow across the lesion cavity and communicate. The alginate strings also contain 
genetically engineered cells that express neurotrophic factors that would further 
enhance neuronal regeneration. The graft has the ability to be stored by freezing 
making them readily available for use and have a PLO filter that would help to 
prevent host immune reaction from affecting the efficacy of the graft. This 
multifunctional graft could now be used for in vivo experiments in animals so that 
they could be optimized for use in humans.  
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6. RECOMMENDATIONS 
 Further studies are needed to further tune the work done in this thesis 
and the recommendations are presented below. 
1. Optimize bundling of strings to keep the strands close together. This would help 
to enhance cell adhesion further. Keeping the strands close together would also 
help to keep the continuity of the graft. The strings should also be close together 
for the graft to act as a bridge at the injury site. 
2. Study of the effect of BDNF released from the Fb/BDNF cells on chick embryo 
dorsal root ganglia. Add chick embryo DRGs to modified alginate strings and 
discs containing Fb/BDNF cells suspended in medium devoid of additional 
growth factors. Observe and quantitate neurite extension and length from the 
DRGs. 
3. Study the effect of a growth factor gradient on neurite extension. Design a 
method to make modified alginate strings or discs with one half containing 
Fb/BDNF and the other half devoid of them. Place DRGs on these grafts and 
observe neurite extension. If the neurites extend towards the side with the 
Fb/BDNF then this design could be used to guide neurites at the injury site. 
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4. Study the effect of loading the enzyme chondroitinase ABC in modified alginate 
strings. The enzyme helps to degrade inhibitory proteoglycans that are present at 
the site of injury. A release profile would have to be performed to study the 
concentration of enzyme released from the strings. The effect of the enzyme on 
ensheathed Fb/BDNF cells on neuronal cell adhesion would also have to be 
verified. These would help to determine if the graft could have additional factors 
that could enhance neuronal regeneration at the injury site. 
5. Study the concentration of peptide (YIGSR/Laminin) loading on the alginate. 
Experiments in this thesis have shown the maximum peptide loading in terms of 
cell adhesion, which is not necessarily the maximum concentration of peptide 
that could be bound to alginate. This might have to be verified by running the 
pure peptide through the high performance liquid chromatography (HPLC) and 
obtaining the range of absorbance and subsequently running the alginate-peptide 
combination. 
6. Study the effects of varying alginate concentrations, calcium ion concentrations 
and peptide concentrations on BDNF release from the strings. Also check for 
BDNF release from strings modified with laminin and compare to strings 
modified with YIGSR. This would help to verify if BDNF release is better with 
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laminin modified strings or if the release would be inhibited by the large laminin 
molecule. 
7. Finally study the effect of the graft in animal models to determine the effect of 
the graft in vivo. Place the modified alginate strings in rat spinal injury models 
and study the effects on neuronal regeneration by doing histopathalogical study 
on some animals and behavioral analysis on others. The histopathalogical 
studies would help to determine the type and length of neurites on the graft and 
the behavioral analysis would help to evaluate the limb functions in the 
paralyzed animals. 
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Appendix A: Protocol for Bioconjugating YIGSR/Laminin to 
alginate 
 
 
 
1.  All glassware should be rinsed first with deionized water and then with 
alcohol and dried under a stream of argon. 
2. Alginate (Manugel DMB, a high G-content alginate) is dissolved in 
MES buffer (0.1 M MES + 0.3 M NaCl, pH 6.5) to obtain a 1 (w/v) 
solution. The pH should be no higher than 6.5 since it affects the 
efficiency of the conjugation process using the carbodimide crosslinker. 
3. Once the alginate is dissolved in the DI water 1-ethyl-3-(3-
dimethylaminopropyl) carbodimide (EDC) is added to activate the 
carboxyl groups in alginate. Different molar concentrations of the 
carboxylic acid groups can be activated by varying the concentration of 
the EDC added. 
4. N-hydroxysulfosuccinimide (sulfo-NHS) is then added at a molar ratio 
of 1:2 to EDC which help to stabilize the intermediate formed between 
EDC and the carboxylic acid groups of alginate. 
5. The activation of the carboxyl acid groups is then allowed to continue 
for 15 minutes by continuously stirring the solution. The appropriate 
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concentration of either YIGSR or laminin is then added. The peptide 
conjugation process is then allowed to proceed for 24 hours by gently 
stirring the solution since vigorous stirring could lead to warming of 
the alginate solution and in turn hinder the peptide conjugation reaction. 
6. Spectra/Por dialysis tubing is cut into several pieces and soaked in 
deionized water for 2 hours to remove any preservatives like sodium 
azide and glycerine. The water is replaced a few times to ensure 
complete removal of any preservatives from the tubing. 
7. The alginate-peptide conjugate is then transferred to the cut and soaked 
pieces of dialysis of tubes and the tubes are sealed with closures. 
8. The dialysis tubes with the modified alginate are then placed in a tank 
containing large volume of deionized water to remove any unreacted 
EDC, sulfo-NHS or peptide. This dialysis process is then allowed to 
continue for 4 days with the water being constantly replaced everyday 
to ensure complete removal of unreacted products. 
9. The dialyzed alginate-peptide conjugate is then transferred to 50ml 
polypropylene centrifuge tubes and placed in a -85ºC freezer till the 
solution is completely frozen. The centrifuge tubes are then placed in a 
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-75ºC freeze dryer that has a vacuum of about 20 millitorrs, for about 4 
days, which turns the alginate peptide conjugate into a dry fibrous form. 
10. The alginate-peptide conjugate is weighed, labeled and then placed in a 
-20ºC freezer for future use. 
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Appendix B: Protocol for counting cells using a haemocytometer 
 
 
 
1. Cells are removed from a culture plate by exposing them to 0.2% 
trypsin EDTA for 3 minutes. The enzyme helps to break the cell 
adhesion moieties that help the cells to adhere to the culture plate. The 
cells are not exposed to trypsin for more than 3 minutes to avoid the 
enzyme from digesting the cells. 
2. After exposure to trypsin the cells are resuspended in growth medium 
containing fetal bovine serum to neutralize the action of trypsin and 
also to break up any cells that might still be adherent to the culture 
plate.  
3. The cells suspended in growth medium are then placed in a 15ml 
centrifuge tube. The contents of the centrifuge tube are centrifuged at 
1000 RPMs for 5 minutes. The cell pellet is then resuspended in 
growth medium to ensure complete removal of trypsin. 
4. 20µl of growth medium with the cells suspended in it is placed in a 
1.5ml microcentrifuge tube. 80µl of 0.4% Trypan blue stain is added to 
the cell suspension. The cells now form 1 in 5 parts of the solution. The 
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solution is then transferred to a hemocytometer using a pipette. 
5. A cover slip is placed over the center of the hemocytometer and the cell 
suspension is added using capillary action by placing the tip of the 
pipette in the groove and just under the cover slip. The centre of the 
hemocytometer has 2 marked square chambers called Neubar’s 
chamber. 
6. The cells in the 4 large corner squares of the chamber, which has 16 
small squares, are counted. The total count is then divided by 4 to get 
average cell count. Since each small square has a volume of 1µl the 
average cell count is then multiplied by 50,000 to get the total cell 
count in 1 ml of medium. 
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Appendix C: Calculations for preparation of YIGSR-alginate conjugate 
 
 
 
Calculations were based on the molecular weight of the individual uronic acid units 
in alginate. 
 
Reactant Molecular Weight 
Mannuronic/Guluronic Acid 194 
EDC 191.7 
Sulfo-NHS 217.1 
YIGSR peptide 594.7 
 
The number of uronic acid residues (carboxyl groups available for activation) in 1g 
of alginate were calculated to be 1/194 = 5.155 x 10-3 moles. 
 
Assuming that 1 mole of EDC would be required to activate 1 mole of carboxylic 
acid groups, the amount of EDC that would be required to activate carboxyl groups 
present in 1g of alginate would be 5.155 x 10-3 moles ~ 0.9882 g 
 
Therefore the amount of EDC that would be required to activate 5% of the 
carboxylic acid groups present in 1g of alginate = 0.9882 g x 0.05 = 0.04947 ~ 50 
mg (2.5775 x 10-4 moles of EDC )  
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Sulfo-NHS was added in the molar ration of 1:2 to EDC. Therefore the amount of 
sulfo-NHS added per g of alginate = (2.5775 x 10-4 moles x 217.1)/2 = 28mg 
 
Number of moles of YIGSR peptide per mg = 0.001/594.7 = 1.6815 x 10-6 moles. 
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concentration of either YIGSR or laminin is then added. The peptide 
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stirring the solution since vigorous stirring could lead to warming of 
the alginate solution and in turn hinder the peptide conjugation reaction. 
6. Spectra/Por dialysis tubing is cut into several pieces and soaked in 
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azide and glycerine. The water is replaced a few times to ensure 
complete removal of any preservatives from the tubing. 
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pieces of dialysis of tubes and the tubes are sealed with closures. 
8. The dialysis tubes with the modified alginate are then placed in a tank 
containing large volume of deionized water to remove any unreacted 
EDC, sulfo-NHS or peptide. This dialysis process is then allowed to 
continue for 4 days with the water being constantly replaced everyday 
to ensure complete removal of unreacted products. 
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polypropylene centrifuge tubes and placed in a -85ºC freezer till the 
solution is completely frozen. The centrifuge tubes are then placed in a 
-75ºC freeze dryer that has a vacuum of about 20 millitorrs, for about 4 
days, which turns the alginate peptide conjugate into a dry fibrous form. 
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also to break up any cells that might still be adherent to the culture 
plate.  
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